<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ziprasidone: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ziprasidone: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ziprasidone: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10040" href="/d/html/10040.html" rel="external">see "Ziprasidone: Drug information"</a> and <a class="drug drug_patient" data-topicid="11154" href="/d/html/11154.html" rel="external">see "Ziprasidone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708843"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Increased mortality in elderly patients with dementia-related psychosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. Ziprasidone is not approved for the treatment of patients with dementia-related psychosis.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F235894"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Geodon</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868641"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Auro-Ziprasidone;</li>
<li>Zeldox</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1043093"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Second Generation (Atypical) Antipsychotic </span></li></ul></div>
<div class="block dop drugH1Div" id="F52812563"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="419949a0-7063-499a-bfea-d3f0bc006ef6">Acute agitation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute agitation:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing</i>: Children ≥5 years and Adolescents: IM: 0.2 mg/kg/dose; maximum dose: 20 mg/dose; a retrospective review of 40 patients (age range: 5 to 18 years) presenting to the emergency department with acute agitation showed a significant (<i>P</i>=0.03) response with a mean initial single dose of 0.19 ± 0.1 mg/kg amongst responders compared to a mean initial dose of 0.13 ± 0.06 mg/kg in nonresponders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28205446']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28205446'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17822344','lexi-content-ref-17201611','lexi-content-ref-15662151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17822344','lexi-content-ref-17201611','lexi-content-ref-15662151'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Children 5 to 11 years: IM: 10 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: IM: 10 to 20 mg; one study (n=59; age range: 5 to 19 years) reported that 69% of 20 mg doses surpassed the desired calming therapeutic effect and caused varying degrees of sedation (4% of patients were unable to be aroused) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17822344']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17822344'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3c79353f-4dd2-48aa-b1f5-7c2968a407c2">Autism spectrum disorders; irritability</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Autism spectrum disorders; irritability:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Oral: Reported <i>final </i>daily dose range: 20 to 240 mg/day in divided doses twice daily; see the following for initial doses and titration reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26091194','lexi-content-ref-18315450','lexi-content-ref-12164181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26091194','lexi-content-ref-18315450','lexi-content-ref-12164181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">A prospective, open-label study of 12 patients (12 to 18 years) used the following individually titrated doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18315450']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18315450'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Patient weight ≤35 kg: Initial: 20 mg every other day at bedtime for 2 doses; then increase dose in weekly increments based on clinical response and tolerability: Week 1: 10 mg twice daily (20 mg/day); Week 2: 20 mg twice daily (40 mg/day); Week 3: 40 mg twice daily (80 mg/day); Week 4: 80 mg twice daily (160 mg/day).</p>
<p style="text-indent:-2em;margin-left:8em;">Patient weight &gt;35 kg: Initial: 20 mg/day at bedtime for 3 doses; then increase dose in weekly increments based on clinical response and tolerability: Week 1: 20 mg twice daily (40 mg/day); Week 2: 40 mg twice daily (80 mg/day); Week 4: 80 mg twice daily (160 mg/day).</p>
<p style="text-indent:-2em;margin-left:6em;">A retrospective trial evaluated 42 pediatric patients (mean age: 11.8 ± 3.9 years; range: 5.9 to 18.7 years) and reported treatment response in 40% of subjects based on improvement in Clinical Global Impressions-Improvement Scale (CGI-I) scores at a mean final dose of 98.7 ± 52 mg/day (1.7 ± 1.1 mg/kg/day); reported range: 20 to 240 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26091194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26091194'])">Ref</a></span>). A case series of 12 patients (8 to 20 years) initiated therapy at 20 mg/day administered at bedtime and then increased by 10 to 20 mg/week divided twice daily based on clinical response and tolerability; final ziprasidone dosage ranged between 20 to 120 mg/day (mean: ~60 mg/day) divided twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12164181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12164181'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d0a6293e-9107-4637-9f4a-4141688c2915">Bipolar I disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar I disorder:</b>
<b>Note:</b> In June 2009, an FDA advisory panel advised that ziprasidone was effective in patients 10 to 17 years of age for the treatment of mixed and manic episodes of bipolar disorder, but did not conclude that it was safe due to large number of subjects lost to follow-up and ambiguity within QTc prolongation data. Since then, prescribing of ziprasidone has decreased similarly for pediatric and adult patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27032095']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27032095'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed dosing</i>: Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DelBello.1','lexi-content-ref-18928413','lexi-content-ref-19018327','lexi-content-ref-Findling.1','lexi-content-ref-24111980','lexi-content-ref-Mechcatie.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DelBello.1','lexi-content-ref-18928413','lexi-content-ref-19018327','lexi-content-ref-Findling.1','lexi-content-ref-24111980','lexi-content-ref-Mechcatie.1'])">Ref</a></span>): Children and Adolescents 10 to 17 years: Oral: Initial dose: 20 mg/day; titrate dose upwards as tolerated, using twice-daily dosing over a 2-week period to the weight-based target range: 60 to 80 mg/day (weight &lt;45 kg) divided into twice-daily doses or 120 to 160 mg/day (weight ≥45 kg) divided into twice-daily doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36282771','lexi-content-ref-24111980','lexi-content-ref-35394365']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36282771','lexi-content-ref-24111980','lexi-content-ref-35394365'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing</i>: Limited data available: Children ≥6 years and Adolescents: An open-label, 8-week study of 21 patients (6 to 17 years [mean: 10.3 years]) with bipolar disorder and comorbid conditions (eg, attention-deficit/hyperactivity disorder, depression, conduct disorder) used the following weight-based dosing regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18076539']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18076539'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Initial dose: 1 mg/kg/day divided twice daily; increase to 1.5 mg/kg/day divided twice daily by Week 2 and increase to 2 mg/kg/day divided twice daily by Week 3 if tolerated; maximum dose: 160 mg/day; <b>Note:</b> Only 14 of the 21 patients completed the study; five dropped out due to lack of efficacy; two dropped out due to adverse reactions; patients experienced a high incidence of sedation (46%) and headaches (38%).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="308cbb9f-ebfb-4bbc-90ee-cd1c4f6c900c">Tourette syndrome, tic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tourette syndrome, tic disorder:</b> Very limited data available: Children and Adolescents 7 to 16 years: Oral: Initial dose: 5 mg/day for 3 days then using twice-daily dosing, titrate dose as tolerated up to 40 mg/day divided twice daily. Dosing is based on a double-blind, placebo-controlled pilot study (n=28); mean daily dose at the end of trial: 28.2 ± 9.6 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10714048']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10714048'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729866"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: There are no pediatric-specific recommendations; based on experience in adult patients, no adjustment may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">IM: There are no pediatric-specific recommendations; cyclodextrin, an excipient in the IM formulation, is cleared by renal filtration; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone is not removed by hemodialysis.</p></div>
<div class="block dohp drugH1Div" id="F52729867"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment is recommended; however, drug undergoes extensive hepatic metabolism and systemic exposure may be increased. Use with caution.</p></div>
<div class="block doa drugH1Div" id="F235897"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10040" href="/d/html/10040.html" rel="external">see "Ziprasidone: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Dose-dependent QTc interval prolongation; consider monitoring ECG during therapy (baseline and after dose increases), particularly in patients with risk factors for QTc prolongation (eg, preexisting QT prolongation, other cardiovascular disease, uncorrected electrolyte abnormalities, concurrent use with other drugs that prolong QT interval) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22452529','lexi-content-ref-24847993']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22452529','lexi-content-ref-24847993'])">Ref</a></span>). Some experts recommend checking baseline ECG in patients with schizophrenia, regardless of risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Oral dose needs to be taken with a meal (≥500 calories) to be adequately absorbed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19026256','lexi-content-ref-20511734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19026256','lexi-content-ref-20511734'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="21dde351-f095-4a55-8b49-bf5298b1e8e6">Agitation/Aggression associated with psychiatric disorders, substance intoxication, or other organic causes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agitation/Aggression (severe, acute) associated with psychiatric disorders (eg, schizophrenia [labeled use], bipolar disorder [off-label use]), substance intoxication (off-label use), or other organic causes (off-label use) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Antipsychotics are appropriate when psychosis is suspected to be the primary cause of agitation/aggression. Other agents are used preferentially in agitation associated with certain intoxications (eg, anticholinergic substances, stimulants) or alcohol withdrawal. Depending on presentation, may combine with a benzodiazepine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moore.2020','lexi-content-ref-22834451','lexi-content-ref-22461918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moore.2020','lexi-content-ref-22834451','lexi-content-ref-22461918'])">Ref</a></span>). For cooperative patients able to take oral medication, use an alternative antipsychotic that does not need to be taken with a meal.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 10 mg every 2 hours <b>or</b> 20 mg every 4 hours (maximum: 40 mg/day). Oral therapy should replace IM administration as soon as possible.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1969751f-c027-4072-874e-d4df29195cbe">Bipolar disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute manic episodes with or without mixed features (labeled use) and acute hypomania, monotherapy (off-label use) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 40 mg twice daily with meal; on day 2 of treatment, may increase to 60 or 80 mg twice daily; subsequently adjust dose based on response and tolerability. Usual dosage: 40 to 80 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29536616','lexi-content-ref-Stovall.2020','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29536616','lexi-content-ref-Stovall.2020','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For some patients, doses up to 240 mg/day may be necessary and tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stovall.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stovall.2020'])">Ref</a></span>). Combining with lithium or valproate for acute episode does not provide additional benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23218157','lexi-content-ref-17404121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23218157','lexi-content-ref-17404121'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance treatment, monotherapy (off-label use) or adjunctive with antimanic therapy (labeled use): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Monotherapy: Oral: </b>Continue dose that was used to achieve control of the acute episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29536616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29536616'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Adjunctive</b>
<b>with antimanic therapy:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 40 or 80 mg twice daily with meal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Despite lack of added benefit for ziprasidone plus lithium or valproate in acute episodes, maintenance treatment with combination treatment may delay time to relapse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20122373','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20122373','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a39de09a-79a2-4eb2-add3-d72d010410df">Delirium in the ICU, hyperactive, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Delirium in the ICU, hyperactive, treatment (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Nonpharmacologic interventions and treatment of underlying conditions are initial steps to prevent and manage delirium. Antipsychotics may be used as short-term adjunctive treatment if distressing symptoms (eg, agitation, anxiety) are present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30113379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30113379'])">Ref</a></span>). Reassess daily for continued need; consider discontinuation and/or taper as symptoms resolve, especially at transitions of care, to prevent unnecessary continuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28049388','lexi-content-ref-26818629','lexi-content-ref-Tietze.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28049388','lexi-content-ref-26818629','lexi-content-ref-Tietze.1'])">Ref</a></span>). Although data are limited, some experts use the following:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 10 mg, then may repeat every 2 hours if needed <b>or</b> 20 mg, then may repeat once in 4 hours if needed; maximum total daily dose: 40 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tietze.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tietze.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 20 to 40 mg every 12 hours with meal, if possible; maximum total daily dose: 80 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20095068','lexi-content-ref-Tietze.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20095068','lexi-content-ref-Tietze.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7834615-81b5-448d-be0f-b6021963e20a">Delusional infestation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Delusional infestation (delusional parasitosis) (off-label use):</b>
<b>Oral:</b> Initial: 20 mg twice daily with meal; gradually increase every few weeks to lowest effective daily dose in range of 20 to 80 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23762722','lexi-content-ref-18794644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23762722','lexi-content-ref-18794644'])">Ref</a></span>). After achieving adequate response, maintain for ≥1 to 3 months before attempting to taper and discontinue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Suh.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Suh.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ce6216e-9365-4809-a16e-1401633c5309">Major depressive disorder, treatment resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder, treatment resistant (unipolar, nonpsychotic) (adjunctive therapy with antidepressant) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Also can be used for initial treatment of major depression <b>with</b> psychotic features (ie, not necessarily treatment resistant) in combination with an antidepressant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rothschild.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rothschild.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 20 mg twice daily with meal; may increase daily dose based on response and tolerability in increments of 40 mg every week up to 160 mg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17685744','lexi-content-ref-26085041']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17685744','lexi-content-ref-26085041'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c642acd-fa55-4d9d-a66b-f25756b729c3">Schizophrenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 20 to 40 mg twice daily with meal; may increase dose based on response and tolerability every 2 days or more. Usual dosage: 20 to 80 mg twice daily; maximum dose: 80 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stroup.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stroup.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For IM administration in acute agitation associated with schizophrenia, refer to "Agitation/Aggression (Severe, Acute) Associated with Psychiatric Disorders, (eg, Schizophrenia [Labeled Use], Bipolar Disorder [Off-Label Use]), Substance Intoxications (Off-Label Use), or Other Organic Causes (Off-Label Use)."</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Discontinuation of therapy</i></b>
<i>:</i> In the treatment of chronic psychiatric disease, switching therapy rather than discontinuation is generally advised if side effects are intolerable or treatment is not effective. If patient insists on stopping treatment, gradual dose reduction (eg, over several weeks to months) is advised to detect a reemergence of symptoms and to avoid withdrawal reactions (ie, agitation, alternating feelings of warmth and chill, anxiety, diaphoresis, dyskinesias, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, vertigo) unless discontinuation is due to significant adverse effects. Monitor closely to allow for detection of prodromal symptoms of disease recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516','lexi-content-ref-17650054','lexi-content-ref-32670542','lexi-content-ref-Post.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516','lexi-content-ref-17650054','lexi-content-ref-32670542','lexi-content-ref-Post.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Switching antipsychotics:</i></b> An optimal universal strategy for switching antipsychotic drugs has not been established. Strategies include cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic) and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). In patients with schizophrenia at high risk of relapse, the current medication may be maintained at full dose as the new medication is increased (ie, overlap); once the new medication is at therapeutic dose, the first medication is gradually decreased and discontinued over 1 to 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039','lexi-content-ref-15949658','lexi-content-ref-28044008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039','lexi-content-ref-15949658','lexi-content-ref-28044008'])">Ref</a></span>). Based upon clinical experience, some experts generally prefer cross-titration and overlap approaches rather than abrupt change (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stroup.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stroup.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991655"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">IM: No dosage adjustment necessary. Cyclodextrin, an excipient in the IM formulation, is cleared by renal filtration; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone is not removed by hemodialysis.</p></div>
<div class="block doha drugH1Div" id="F50988958"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, drug undergoes extensive hepatic metabolism and systemic exposure may be increased.  Use with caution.</p></div>
<div class="block arsc drugH1Div" id="F58703382"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">CNS depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">CNS depressive symptoms, including <b>drowsiness</b> and somnolence have been reported with ziprasidone and may cause nonadherence and impair physical and/or mental abilities resulting in subsequent falling and fracture, particularly in older adults.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related, related to the pharmacologic action; somnolence is believed to be due to histamine-1 receptor antagonism leading to potential CNS depressant effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27372312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27372312'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic (ziprasidone is considered to be moderately sedating at usual therapeutic doses in comparison with other antipsychotics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27372312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27372312'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27372312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27372312'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent administration with other CNS depressants (eg, benzodiazepines, antihistamines) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27372312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27372312'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dyslipidemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics are associated with dyslipidemia in adult and pediatric patients, which is a component of the metabolic syndrome observed with this pharmacologic class. Of the second-generation antipsychotics, ziprasidone is associated with a low risk of causing lipid abnormalities; however, <b>hypercholesterolemia</b> has been observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37391174','lexi-content-ref-15869022','lexi-content-ref-28721057','lexi-content-ref-32237292']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37391174','lexi-content-ref-15869022','lexi-content-ref-28721057','lexi-content-ref-32237292'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; increases in cholesterol have been reported within 2 to 4 weeks of antipsychotic initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32237292']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32237292'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (regardless of medication use) is associated with a higher rate of morbidity/mortality compared to the general population, primarily due to cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15151456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15151456'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Extrapyramidal symptoms</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone may cause <b>extrapyramidal reaction</b>, also known as drug-induced movement disorders. Antipsychotics cause four main extrapyramidal symptoms (EPS): Acute <b>dystonia</b>, drug-induced parkinsonism, <b>akathisia</b>, and <b>tardive dyskinesia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15349021','lexi-content-ref-24995318','lexi-content-ref-14702272','lexi-content-ref-20187598','lexi-content-ref-23698184','lexi-content-ref-28721057','lexi-content-ref-30192094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15349021','lexi-content-ref-24995318','lexi-content-ref-14702272','lexi-content-ref-20187598','lexi-content-ref-23698184','lexi-content-ref-28721057','lexi-content-ref-30192094'])">Ref</a></span>). EPS presenting as <b>dysphagia</b>, esophageal dysmotility, or aspiration have also been reported with antipsychotics, which may not be recognized as EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> EPS: Dose-related; due to antagonism of dopaminergic D<sub>2</sub> receptors in nigrostriatal pathways (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12927004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12927004'])">Ref</a></span>). Tardive dyskinesia: Time-related (delayed); results from chronic exposure to D<sub>2</sub> receptor antagonists leading to up-regulation of these receptors over time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23858394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23858394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Acute dystonia:</span> Rapid; in the majority of cases, dystonia usually occurs within the first 5 days after initiating antipsychotic therapy (even with the first dose, particularly in patients receiving parenteral antipsychotics) or a dosage increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Drug-induced parkinsonism: </span>Varied; onset may be delayed from days to weeks, with 50% to 75% of cases occurring within 1 month and 90% within 3 months of antipsychotic initiation, a dosage increase, or a change in the medication regimen (such as adding another antipsychotic agent or discontinuing an anticholinergic medication) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Akathisia: </span>Varied; may begin within several days after antipsychotic initiation but usually increases with treatment duration, occurring within 1 month in up to 50% of cases, and within 3 months in 90% of cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Tardive dyskinesia:</span> Delayed; symptoms usually appear after 1 to 2 years of continuous exposure to a D<sub>2</sub> receptor antagonist and almost never before 3 months, with an insidious onset, evolving into a full syndrome over days and weeks, followed by symptom stabilization, and then a chronic waxing and waning of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23858394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23858394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Esophageal dysfunction (associated with EPS): </span>Varied; ranges from weeks to months following initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14565800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14565800'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">EPS (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Prior history of EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Younger age (in general, children and adolescents are usually at higher risk for EPS compared to adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18533766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18533766'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific antipsychotic: Ziprasidone is usually associated with a low propensity to cause EPS compared to other antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17627670','lexi-content-ref-20187598','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17627670','lexi-content-ref-20187598','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Acute dystonia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Young age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced parkinsonism:</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Akathisia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher antipsychotic dosages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Polypharmacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Mood disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Tardive dyskinesia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Acute motor symptoms (eg, parkinsonism symptoms, Parkinson disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;55 years, females &gt;55 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Cognitive impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant treatment with anticholinergic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diagnosis of schizophrenia or affective disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31325958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31325958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Greater total antipsychotic exposure (especially first-generation antipsychotics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Poor treatment response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Substance misuse or dependence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Race (White or African descent). <b>Note:</b> Although early literature supported race as a potential risk factor for tardive dyskinesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8102845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8102845'])">Ref</a></span>), newer studies have challenged this assertion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28146614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28146614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Esophageal dysfunction (associated with EPS):</p>
<p style="text-indent:-2em;margin-left:8em;">• Certain comorbidities such as neurologic degenerative disease, dementia, stroke, Parkinson disease, or myasthenia gravis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Adults &gt;75 years of age (may be risk factor due to age-related muscle atrophy, cognitive impairment, reduced esophageal peristalsis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic abnormalities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agranulocytosis</b>, <b>leukopenia</b>, and <b>thrombocytopenia</b> have been reported with ziprasidone. Neutropenia has been reported with other second-generation antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16377373','lexi-content-ref-15765830']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16377373','lexi-content-ref-15765830'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; in general, drug-induced neutropenia usually manifests after 1 or 2 weeks of exposure and agranulocytosis usually appears 3 to 4 weeks following initiation of therapy; however, the onset may be insidious (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18098216','lexi-content-ref-3819263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18098216','lexi-content-ref-3819263'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of drug-induced leukopenia/neutropenia and preexisting low white blood cell count/absolute neutrophil count</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18098216','lexi-content-ref-3819263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18098216','lexi-content-ref-3819263'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics are associated with <b>hyperglycemia</b> in adult and pediatric patients, to varying degrees, which is a component of the metabolic syndrome observed with the pharmacologic class (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37391174']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37391174'])">Ref</a></span>). Ziprasidone is associated with a low risk of causing metabolic alterations in adult patients; however, glycemic abnormalities ranging from hyperglycemia to <b>diabetes mellitus</b>, and <b>hyperglycemic hyperosmolar syndrome</b> have been observed rarely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26792761','lexi-content-ref-17627670','lexi-content-ref-23680062','lexi-content-ref-21881458','lexi-content-ref-20520598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26792761','lexi-content-ref-17627670','lexi-content-ref-23680062','lexi-content-ref-21881458','lexi-content-ref-20520598'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; with antipsychotics in general, new-onset diabetes has been observed within the first 3 months to a median onset of 3.9 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20520598','lexi-content-ref-18348593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20520598','lexi-content-ref-18348593'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• African-American race (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &lt;35 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Preexisting obesity, poor exercise habits, or other risk factors for diabetes, including family history of diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Exposure to other agents that also increase the risk of hyperglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific antipsychotic: Ziprasidone is associated with a low to moderate risk of metabolic disturbances (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-26792761','lexi-content-ref-20187598','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-26792761','lexi-content-ref-20187598','lexi-content-ref-28721057'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperprolactinemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone is typically associated with a lower risk of causing significant effects on prolactin compared to other second-generation antipsychotics with a higher risk (such as risperidone), although there are case reports of <b>hyperprolactinemia</b> in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28223031','lexi-content-ref-15465997','lexi-content-ref-24677189','lexi-content-ref-20871665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28223031','lexi-content-ref-15465997','lexi-content-ref-24677189','lexi-content-ref-20871665'])">Ref</a></span>). Hyperprolactinemia may lead to gynecomastia, galactorrhea not associated with childbirth, amenorrhea, sexual disorder, and infertility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19958039','lexi-content-ref-19113797','lexi-content-ref-27825323','lexi-content-ref-15456328','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19958039','lexi-content-ref-19113797','lexi-content-ref-27825323','lexi-content-ref-15456328','lexi-content-ref-28721057'])">Ref</a></span>). Although long-term effects of elevated prolactin levels have not been fully evaluated, some studies suggest a possible association between hyperprolactinemia and an increased risk for breast and/or pituitary tumors and osteopenia/osteoporosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23983962','lexi-content-ref-19113797','lexi-content-ref-20331935','lexi-content-ref-16633146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23983962','lexi-content-ref-19113797','lexi-content-ref-20331935','lexi-content-ref-16633146'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Related to the pharmacologic action; antagonism of dopamine D<sub>2</sub> receptors in the tuberoinfundibular dopaminergic pathway causes disinhibition of prolactin release resulting in hyperprolactinemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19958039','lexi-content-ref-28223031']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19958039','lexi-content-ref-28223031'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; typically within a few weeks following initiation, but may also arise after long-term, stable use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598','lexi-content-ref-24677189']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598','lexi-content-ref-24677189'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Ziprasidone is considered a prolactin-sparing antipsychotic with a low risk for hyperprolactinemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19958039','lexi-content-ref-28223031']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19958039','lexi-content-ref-28223031'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19113797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19113797'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (particularly those of reproductive age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19958039','lexi-content-ref-19113797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19958039','lexi-content-ref-19113797'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersensitivity reaction,</b> including <b>angioedema</b>, <b>skin rash</b>, and <b>urticaria</b>, have been reported with ziprasidone. <b>Drug reaction with eosinophilia and systemic symptoms</b> (DRESS) and severe cutaneous adverse reactions (SCARs) (ie, <b>Stevens-Johnson syndrome</b>) have also been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Hypersensitivity reactions: Delayed hypersensitivity reactions, including SCARs, are T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; in one case report, systemic hypersensitivity reaction with pruritic skin rash occurred 3 weeks following ziprasidone initiation; symptoms recurred 2 days after ziprasidone rechallenge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117439']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117439'])">Ref</a></span>). In another case report, urticaria and angioedema occurred 27 days and 30 days, respectively, following ziprasidone initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17446198']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17446198'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Mortality in older adults</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Older adults with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to those treated with placebo. Although the causes of death were varied, most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17548409','lexi-content-ref-24416588','lexi-content-ref-25786075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17548409','lexi-content-ref-24416588','lexi-content-ref-25786075'])">Ref</a></span>). In addition, an increased incidence of cerebrovascular effects, including fatalities, have been reported in placebo-controlled trials of other second-generation antipsychotics in older adults with dementia-related psychosis. Of note, ziprasidone is not approved for the treatment of dementia-related psychosis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unknown; possible mechanisms include arrhythmia, cardiac arrest, and extrapyramidal effects that may increase the risk of falls, aspirations, and pneumonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24016844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24016844'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Dementia-related psychosis (eg, Lewy body dementia, Parkinson disease dementia)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i> Higher antipsychotic dosage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25140533','lexi-content-ref-25786075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25140533','lexi-content-ref-25786075'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuroleptic malignant syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">All antipsychotics have been associated with <b>neuroleptic malignant syndrome</b> (NMS), although the incidence is lower with second-generation (atypical) antipsychotics compared to first-generation (typical) antipsychotics. There are case reports of NMS with ziprasidone, including monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33763185','lexi-content-ref-16352776','lexi-content-ref-12454565','lexi-content-ref-17366349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33763185','lexi-content-ref-16352776','lexi-content-ref-12454565','lexi-content-ref-17366349'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Idiosyncratic; possibly due to a reduction in CNS dopaminergic tone, along with dysregulation of autonomic nervous system activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25578944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25578944'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; in general, most patients develop NMS within 2 weeks of antipsychotic initiation or dose increase. In some patients, prodromal symptoms emerge within an hour of initiation; once the syndrome starts, the full syndrome usually develops in 3 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16352776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16352776'])">Ref</a></span>). However, NMS may also occur months after stable antipsychotic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12766935']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12766935'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Males (twice as likely to develop NMS compared to females) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9735957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9735957'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• High-dose antipsychotic treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant lithium or benzodiazepine (potential risk factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Catatonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Polypharmacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Pharmacokinetic interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• IM administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Rapid dosage escalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Psychomotor agitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone may cause <b>orthostatic hypotension</b> (although at a lower prevalence compared to first-generation antipsychotics and certain second-generation antipsychotics, such as clozapine, risperidone, and quetiapine) and accompanying <b>tachycardia</b>, <b>dizziness</b>, and <b>syncope</b> in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24649390','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24649390','lexi-content-ref-28721057'])">Ref</a></span>). Orthostatic hypotension may result in subsequent falls and fractures, particularly in older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25581312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25581312'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Related to pharmacologic action; orthostatic hypotension is thought to be due to alpha-1 adrenergic receptor antagonism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24649390','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24649390','lexi-content-ref-28721057'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; per manufacturer's labeling, orthostatic hypotension is most common during initial dose titration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cerebrovascular disease</p>
<p style="text-indent:-2em;margin-left:6em;">• Conditions which would predispose patients to hypotension (dehydration, hypovolemia, treatment with antihypertensive agents)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">QT prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone is associated with <b>prolonged QT interval on ECG</b> in adult and pediatric patients, including reports of <b>torsades de pointes</b> (TdP), predominantly in the setting of multiple risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36282771','lexi-content-ref-15608546','lexi-content-ref-35394365','lexi-content-ref-16684946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36282771','lexi-content-ref-15608546','lexi-content-ref-35394365','lexi-content-ref-16684946'])">Ref</a></span>). Of the second-generation antipsychotics, ziprasidone is associated with a higher risk of QTc prolongation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23295003','lexi-content-ref-36515735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23295003','lexi-content-ref-36515735'])">Ref</a></span>). In clinical trials, the average increase in QTc following oral ziprasidone was approximately 5 to 23 ms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22452529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22452529'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; ziprasidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16684946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16684946'])">Ref</a></span>), although other mechanisms may also be involved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36515735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36515735'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced QTc prolongation/TdP (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996','lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996','lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with a reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QTc interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypokalemia, hypocalcemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Coadministration of multiple medications (≥2) that prolong the QT interval or increase drug interactions that increase serum drug concentrations of QTc prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Substance use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20210726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20210726'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Temperature dysregulation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics may impair the body’s ability to regulate core body temperature, which may contribute to an elevation in core body temperature during predisposing conditions such as strenuous exercise or dehydration. <b>Hypothermia </b>has been reported with ziprasidone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18606348','lexi-content-ref-23251855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18606348','lexi-content-ref-23251855'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non–dose-related; idiosyncratic. Exact mechanism is unknown; however, body temperature is regulated by the hypothalamus with involvement of the dopamine, serotonin, and norepinephrine neurotransmitters. D<sub>2 </sub>antagonism may cause an increase in body temperature, while 5-HT<sub>2A</sub> (serotonin) receptor antagonism may cause a decrease in body temperature. Of note, ziprasidone has stronger affinity for 5-HT<sub>2A</sub> receptors than for D<sub>2</sub> receptors, suggesting that it is more likely to cause a reduction in body temperature than an increase. In addition, antagonism of peripheral alpha-1 adrenergic receptors has also been suggested as a factor in the hypothermic effect by inhibiting peripheral responses to cooling (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18606348','lexi-content-ref-23251855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18606348','lexi-content-ref-23251855'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Hypothermia: Varied; antipsychotic-induced hypothermia cases indicate a typical onset in the period shortly after initiation of therapy or a dosage increase (first 7 to 10 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28936184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Heat stroke:</p>
<p style="text-indent:-2em;margin-left:8em;">• Psychiatric illness (regardless of medication use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9712220','lexi-content-ref-17698676','lexi-content-ref-18941580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9712220','lexi-content-ref-17698676','lexi-content-ref-18941580'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Strenuous exercise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Heat exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant medications possessing anticholinergic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Hypothermia:</p>
<p style="text-indent:-2em;margin-left:8em;">• In general, predisposing risk factors include: Older adults, cerebrovascular accident, preexisting brain damage, hypothyroidism, malnutrition, shock, sepsis, adrenal insufficiency, diabetes, disability, burns, exfoliative dermatitis benzodiazepine use, alcohol intoxication, kidney or liver failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28936184'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Schizophrenia (regardless of antipsychotic use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17401555']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17401555'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Weight gain</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone is associated with significant <b>weight gain</b> (increase of ≥7% from baseline) in adult and pediatric patients, which is a component of the metabolic syndrome observed with this pharmacologic class.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Multiple proposed mechanisms, including actions at serotonin, dopamine, histamine, and muscarinic receptors, with differing effects explained by differing affinity of antipsychotics at these receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731','lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731','lexi-content-ref-26218604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; antipsychotic-induced weight gain usually occurs rapidly in the initial period following initiation, then gradually decreases and flattens over several months with patients continuing to gain weight in the long term (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Parental BMI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-15823759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-15823759'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid weight gain in the initial period: Younger age, lower baseline BMI, more robust response to antipsychotic, and increase in appetite; rapid weight gain of &gt;5% in the first month has been observed as the best predictor for significant long-term weight gain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (although weight gain plateaus, patients continue to gain weight over time) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (regardless of medication) is associated with a higher prevalence of obesity compared to the general population due to components of the illness, such as negative symptoms, sedentary lifestyles, and unhealthy diets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861176'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Ziprasidone is considered to have a low propensity for causing weight gain; olanzapine and clozapine are associated with a high risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731','lexi-content-ref-22009159','lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731','lexi-content-ref-22009159','lexi-content-ref-20187598'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F235859"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequencies represent oral administration in adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (4% to 16%)<span class="lexi-table-link-container"> (<a aria-label="Weight Gain table link" class="lexi-table-link" data-table-id="lexi-content-weight-gain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-weight-gain')">table 1</a>)</span><span class="table-link" style="display:none;">Weight Gain</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Weight Gain" frame="border" id="lexi-content-weight-gain" rules="all">
<caption style="text-align:center;">
<b>Ziprasidone: Adverse Reaction: Weight Gain</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ziprasidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ziprasidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60 to 80 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">388</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">451</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 to 40 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">295</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">451</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">80 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">97</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">227</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">100 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">74</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">227</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">40 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">135</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">227</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">167</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">227</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">109</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">227</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (IM and oral: 8% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (IM and oral: 3% to 16%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 2</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, drowsiness (IM: 8% to 20%; oral: 14% to 31%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 3</a>)</span><span class="table-link" style="display:none;">Drowsiness</span>, extrapyramidal reaction (14% to 31%)<span class="lexi-table-link-container"> (<a aria-label="Extrapyramidal Reaction table link" class="lexi-table-link" data-table-id="lexi-content-extrapyramidal-reaction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-extrapyramidal-reaction')">table 4</a>)</span><span class="table-link" style="display:none;">Extrapyramidal Reaction</span>, headache (IM and oral: 5% to 18%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Ziprasidone: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ziprasidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ziprasidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Agitation in schizophrenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">41</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Agitation in schizophrenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">63</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">40 to 80 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Manic and mixed episodes associated with bipolar disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">279</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">136</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">702</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">273</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Ziprasidone: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ziprasidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ziprasidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Agitation in schizophrenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">41</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Agitation in schizophrenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">63</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">40 to 80 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Manic and mixed episodes associated with bipolar disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">279</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">136</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">702</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">273</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Extrapyramidal Reaction" frame="border" id="lexi-content-extrapyramidal-reaction" rules="all">
<caption style="text-align:center;">
<b>Ziprasidone: Adverse Reaction: Extrapyramidal Reaction</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ziprasidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ziprasidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">40 to 80 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Manic and mixed episodes associated with bipolar disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">279</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">136</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">702</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">273</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (IM and oral: ≤2%), chest pain (3%), hypertension (3%), orthostatic hypotension (IM: 5%, oral: ≥1%), tachycardia (2%)<span class="lexi-table-link-container"> (<a aria-label="Tachycardia table link" class="lexi-table-link" data-table-id="lexi-content-tachycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-tachycardia')">table 5</a>)</span><span class="table-link" style="display:none;">Tachycardia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Tachycardia" frame="border" id="lexi-content-tachycardia" rules="all">
<caption style="text-align:center;">
<b>Ziprasidone: Adverse Reaction: Tachycardia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ziprasidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ziprasidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">702</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">273</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (IM: 2%), fungal dermatitis (2%), furunculosis (IM: 2%), skin photosensitivity (≥1%), skin rash (4% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (IM: 2%; oral: ≥1%), anorexia (IM and oral: 2%), constipation (IM: 2%; oral: 9%), diarrhea (IM and oral: 3% to 5%), dyspepsia (IM and oral: 2% to 8%), dysphagia (2%)<span class="lexi-table-link-container"> (<a aria-label="Dysphagia table link" class="lexi-table-link" data-table-id="lexi-content-dysphagia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dysphagia')">table 6</a>)</span><span class="table-link" style="display:none;">Dysphagia</span>, rectal hemorrhage (IM and oral: ≤2%), sialorrhea (4%), vomiting (IM and oral: 3% to 5%), xerostomia (4% to 5%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dysphagia" frame="border" id="lexi-content-dysphagia" rules="all">
<caption style="text-align:center;">
<b>Ziprasidone: Adverse Reaction: Dysphagia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ziprasidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ziprasidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">40 to 80 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Manic and mixed episodes associated with bipolar disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">279</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">136</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (IM: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema (≥1%), tongue edema (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site (IM: 7% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait (≥1%), agitation (IM: 2%; oral: ≥1%), akathisia (IM: 2%; oral: 8% to 10%)<span class="lexi-table-link-container"> (<a aria-label="Akathisia table link" class="lexi-table-link" data-table-id="lexi-content-akathisia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-akathisia')">table 7</a>)</span><span class="table-link" style="display:none;">Akathisia</span>, akinesia (≥1%), amnesia (≥1%), anxiety (5%), asthenia (5% to 6%), ataxia (≥1%), buccoglossal syndrome (≥1%), chills (≥1%), choreoathetosis (≥1%), cogwheel rigidity (≥1%), confusion (≥1%), delirium (≥1%), dysarthria (≥1%), falling (≥1%), hostility (≥1%), hypertonia (≥1%), hypoesthesia (2%), hypothermia (≥1%), hypotonia (≥1%), neuropathy (≥1%), paresthesia (IM: 2%; oral: ≥1%), personality disorder (IM: 2%), speech disturbance (IM and oral: 2%), tremor (≥1%), twitching (≥1%), vertigo (≥1%), withdrawal syndrome (≥1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Akathisia" frame="border" id="lexi-content-akathisia" rules="all">
<caption style="text-align:center;">
<b>Ziprasidone: Adverse Reaction: Akathisia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ziprasidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ziprasidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Agitation in schizophrenic patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">63</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">40 to 80 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Manic and mixed episodes associated with bipolar disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">279</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">136</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">702</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">273</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia (≥1%), dystonia (≥1%), hyperkinetic muscle activity (≥1%), hypokinesia (≥1%), myalgia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia (≥1%), oculogyric crisis (≥1%), visual disturbance (3% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Flank pain (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (2%), flu-like symptoms (≥1%), increased cough (3%), pharyngitis (3%), respiratory tract infection (8%), rhinitis (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (4%), fever (≥1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris, atrial fibrillation, bundle branch block, cardiomegaly, deep vein thrombophlebitis, first-degree atrioventricular block, myocarditis, peripheral edema, phlebitis, pulmonary embolism, syncope, thrombophlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, contact dermatitis, ecchymoses, eczema, exfoliative dermatitis, maculopapular rash, urticaria, vesicobullous dermatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria, amenorrhea, decreased glucose tolerance, dehydration, gynecomastia, heavy menstrual bleeding, hyperchloremia, hypercholesterolemia, hyperglycemia, hyperkalemia, hyperlipidemia, hyperthyroidism, hyperuricemia, hypocalcemia, hypochloremia, hypocholesterolemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypothyroidism, increased lactate dehydrogenase, increased thirst, ketosis, respiratory alkalosis, thyroiditis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Fecal impaction, gingival hemorrhage, hematemesis, melena, oral leukoplakia, oral paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Anorgasmia, ejaculatory disorder, erectile dysfunction, female sexual disorder, glycosuria, hematuria, lactation, male sexual disorder, nocturia, oliguria, polyuria, urinary retention, uterine hemorrhage, vaginal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, basophilia, eosinophilia, hemophthalmos, hypochromic anemia, hypoproteinemia, leukocytosis, leukopenia, lymphadenopathy, lymphedema, lymphocytosis, monocytosis, polycythemia, thrombocytopenia, thrombocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice, hepatitis, hepatomegaly, increased gamma-glutamyl transferase, increased serum alkaline phosphatase, increased serum transaminases, jaundice, liver steatosis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebral infarction, cerebrovascular accident, hyperreflexia, myoclonus, opisthotonus, paralysis, seizure, trismus</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Gout, increased creatine phosphokinase in blood specimen, myopathy, tenosynovitis, torticollis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharitis, cataract, conjunctivitis, dry eye syndrome, keratitis, keratoconjunctivitis, nystagmus disorder, photophobia, visual field defect</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis, hemoptysis, laryngismus, pneumonia</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Neuromuscular &amp; skeletal: Arthralgia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Prolonged QT interval on ECG (Atkinson 2022, Blair 2004, Camm 2012, Findling 2022), torsades de pointes (Heinrich 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus (Greenberg 2007), galactorrhea not associated with childbirth (Raza 2010), hyperglycemic hyperosmolar syndrome (Létourneau 2011), hyperprolactinemia (Lusskin 2004)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Priapism (Karamustafalioglu 2013), urinary incontinence</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Montgomery 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms (Chan 2015), hypersensitivity reaction (including allergic dermatitis, angioedema, orofacial edema) (Akkaya 2007), swollen tongue</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Facial nerve paralysis, hypomania, insomnia, mania, neuroleptic malignant syndrome (Ozen 2007), serotonin syndrome (Lin 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tardive dyskinesia (Ananth 2004)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sleep apnea (obstructive) (Shirani 2011)</p></div>
<div class="block coi drugH1Div" id="F235873"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to ziprasidone or any component of the formulation; history of (or current) prolonged QT; congenital long QT syndrome; recent myocardial infarction; uncompensated heart failure; concurrent use of other QT<sub>c</sub>-prolonging agents including arsenic trioxide, chlorpromazine, class Ia antiarrhythmics (eg, disopyramide, quinidine, procainamide), class III antiarrhythmics (eg, amiodarone, dofetilide, ibutilide, sotalol), dolasetron, droperidol, gatifloxacin, halofantrine, levomethadyl, mefloquine, mesoridazine, moxifloxacin, pentamidine, pimozide, probucol, sparfloxacin, tacrolimus, and thioridazine</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F235857"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use is contraindicated in patients with recent acute myocardial infarction (MI), QT prolongation, or uncompensated heart failure. Avoid use in patients with a history of cardiac arrhythmias; use with caution in patients with history of MI or unstable heart disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic disease or impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predisposing factors.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Intramuscular formulation: Use the intramuscular formulation with caution in patients with renal impairment; formulation contains cyclodextrin, an excipient which may accumulate in renal insufficiency, although the clinical significance of this finding is uncertain (Luke 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>
<b>Other warnings/precautions</b>:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: When discontinuing antipsychotic therapy, gradually taper antipsychotics to avoid physical withdrawal symptoms and rebound symptoms (APA [Keepers 2020]; WFSBP [Hasan 2012]). Withdrawal symptoms may include agitation, alternating feelings of warmth and cold, anxiety, diaphoresis, dyskinesia, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, and vertigo (Lambert 2007; Moncrieff 2020). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anticholinergic or dopaminergic antipsychotics (Cerovecki 2013). Patients with chronic symptoms, repeated relapses, and clear diagnostic features of schizophrenia are at risk for poor outcomes if medications are discontinued (APA [Keepers 2020]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878677"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In June 2009, an FDA advisory panel advised that ziprasidone is effective in patients 10 to 17 years of age for the treatment of mixed and manic episodes of bipolar disorder, but did not conclude that it was safe due to a large number of subjects lost to follow-up and ambiguity within QTc prolongation data. Since then, prescribing of ziprasidone has decreased similarly for pediatric and adult patients (Wang 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Pediatric psychiatric disorders are frequently serious mental disorders which present with variable symptoms that do not always match adult diagnostic criteria. Conduct a thorough diagnostic evaluation and carefully consider risks of psychotropic medication before initiation in pediatric patients. Medication therapy for pediatric patients with bipolar disorder is indicated as part of a total treatment program that frequently includes educational, psychological, and social interventions. A systematic review and meta-analysis of trials (n=2,158; age range: 8 to 19 years old) reported inferior efficacy of ziprasidone compared to other agents (aripiprazole, asenapine, paliperidone, risperidone, quetiapine, olanzapine, molindone) for youth with early-onset schizophrenia (Pagsberg 2017). Another systematic review evaluating the effect and safety of atypical antipsychotics for treatment of disruptive behavior disorders in children and youths noted a lack of evidence to support ziprasidone in children ≥5 years and youth and no evidence for children &lt;5 years of age (Loy 2017).</p></div>
<div class="block foc drugH1Div" id="F235867"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Geodon: 20 mg, 40 mg, 60 mg, 80 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 40 mg, 60 mg, 80 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intramuscular, as mesylate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intramuscular, as mesylate [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Geodon: 20 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F235853"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F235876"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Geodon Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $28.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $28.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $34.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $34.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Ziprasidone HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $8.00 - $8.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $8.00 - $8.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $9.83 - $10.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $9.83 - $10.88</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Geodon Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $73.63</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Ziprasidone Mesylate Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $23.89 - $56.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868642"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zeldox: 20 mg, 40 mg, 60 mg, 80 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 40 mg, 60 mg, 80 mg</p></div>
<div class="block exp drugH1Div" id="F10806709"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>2.5 mg/mL Oral Solution</b></p>
<p style="text-indent:-2em;margin-left:4em;">A 2.5 mg/mL oral solution may be made with ziprasidone mesylate injection and Ora-Sweet. Reconstitute 8 vials of the 20 mg injectable powder. Each vial should be reconstituted with 1.2 mL of distilled water resulting in a 20 mg/mL ziprasidone solution. Once dissolved, transfer 7.5 mL of the ziprasidone solution to a calibrated amber bottle. Further dilute by adding a sufficient quantity of Ora-Sweet to make 60 mL resulting in a final concentration of 2.5 mg/mL. Label "refrigerate" and "protect from light." Stable for 42 days refrigerated.</p>
<div class="reference">Green K and Parish RC, "Stability of Ziprasidone Mesylate in an Extemporaneously Compounded Oral Solution," <i>J Pediatr Pharmacol Ther</i>, 2010, 15:138-41.</div>
</div>
<div class="block admp drugH1Div" id="F52614033"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer capsule with food (in adults, ≥500 calories) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20511734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20511734'])">Ref</a></span>). Swallow capsule whole; do not open, crush, or chew capsules.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: For IM use only; do not administer IV.</p></div>
<div class="block adm drugH1Div" id="F235870"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer capsule with food (≥500 calories) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20511734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20511734'])">Ref</a></span>). Swallow capsule whole; do not open, crush, or chew capsules.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Injection:</b> For IM administration only.</p></div>
<div class="block hazard drugH1Div" id="F49132851"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F235887"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule: Store at 25°C (77°F); excursion permitted to 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Vials for injection: Store at 25°C (77°F); excursion permitted to 15°C to 30°C (59°F to 86°F).  Protect from light. Following reconstitution, injection may be stored at room temperature up to 24 hours or under refrigeration for up to 7 days. Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53569534"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Treatment of schizophrenia (FDA approved in adults); treatment of bipolar disorder with acute mania or mixed features with or without psychosis as monotherapy (FDA approved in adults); maintenance adjunctive therapy (to lithium or valproate) for bipolar I disorder (FDA approved in adults). <b>Note:</b> Due to its greater capacity to prolong the QT interval, ziprasidone is generally not considered to be a first-line agent.</p>
<p style="text-indent:-2em;margin-left:4em;">Has also been used in children and adolescents for treatment of Tourette syndrome, tic disorders, and irritability associated with autism spectrum disorders.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: Acute agitation in patients with schizophrenia (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F10524190"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ziprasidone may be confused with TraZODone</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older due to an increased risk of stroke and a greater rate of cognitive decline and mortality in patients with dementia. Evidence also suggests there may be an increased risk of mortality with use independent of dementia. Avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. Use of antipsychotics may be appropriate for labeled indications including schizophrenia, bipolar disorder, Parkinson disease psychosis, adjunctive therapy in major depressive disorder, or for short-term use as an antiemetic (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F235911"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F235861"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents With Seizure Threshold Lowering Potential: May enhance the adverse/toxic effect of Ziprasidone. Specifically, the risk of seizures may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Amiodarone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Amisulpride (Oral).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even greater risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (Second Generation [Atypical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Consider avoiding atypical antipsychotic use in patients with Parkinson disease. If an atypical antipsychotic is necessary, consider using clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arsenic Trioxide: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Arsenic Trioxide.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Astemizole: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Astemizole.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Azithromycin (Systemic).  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Bedaquiline.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabergoline: May diminish the therapeutic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbetocin: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Chloroquine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of ChlorproMAZINE.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cisapride: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Cisapride.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Citalopram. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clarithromycin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clofazimine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of CloZAPine.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Ziprasidone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ziprasidone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Dasatinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delamanid: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Delamanid.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Domperidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Donepezil: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxepin-Containing Products: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Doxepin-Containing Products.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Dronedarone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the QTc-prolonging effect of Ziprasidone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of Ziprasidone. Encorafenib may decrease the serum concentration of Ziprasidone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias, and decreased ziprasidone concentrations. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Escitalopram.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etelcalcetide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias (including TdP) with a continuous overnight ECG when fingolimod is combined with QT prolonging drugs. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flecainide.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Fluconazole. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flupentixol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gadobenate Dimeglumine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Gadobenate Dimeglumine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Galantamine: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemifloxacin: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. If use is necessary, monitor for QTc interval prolongation and arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Halofantrine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Huperzine A: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iboga: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipramine: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotuzumab Ozogamicin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Inotuzumab Ozogamicin.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levofloxacin-Containing Products (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Lofexidine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meglumine Antimoniate: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to one of these agents when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Midostaurin.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Moxifloxacin (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Moxifloxacin (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Nilotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of OLANZapine.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Ondansetron.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Osimertinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxytocin: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pacritinib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Papaverine: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Papaverine.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic).  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pilsicainide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pilsicainide.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pimozide.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Piperaquine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probucol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Probucol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Indeterminate Risk - Avoid): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Indeterminate Risk - Caution): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IA Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class III Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk).  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Miscellaneous Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of QUEtiapine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of QuiNINE.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Ribociclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: QT-prolonging Agents (Highest Risk) may enhance the CNS depressant effect of RisperiDONE. QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of RisperiDONE.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparfloxacin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Sparfloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of SUNItinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terbutaline: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terfenadine: May enhance the QTc-prolonging effect of Ziprasidone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for NMS and extrapyramidal symptoms may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Thioridazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Toremifene.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Vemurafenib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F235889"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Administration with a meal containing at least 500 calories increases serum levels ~80%. Management: Administer with a meal containing at least 500 calories (Lincoln 2010).</p></div>
<div class="block dic drugH1Div" id="F9626986"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Capsule: Take with food.</p></div>
<div class="block rep_considerations drugH1Div" id="F54231621"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Ziprasidone may cause hyperprolactinemia, which may cause a reversible reduction of reproductive function in females.</p>
<p style="text-indent:0em;margin-top:2em;">If treatment is needed in a woman planning a pregnancy, use of an agent other than ziprasidone may be preferred (Grunze 2018; Larsen 2015).</p></div>
<div class="block pri drugH1Div" id="F235877"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and/or withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.</p>
<p style="text-indent:0em;margin-top:2em;">The American College of Obstetricians and Gynecologists recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy are limited and routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to a typical antipsychotic that the fetus has not yet been exposed to; consider risk:benefit (ACOG 2008). If treatment is initiated during pregnancy, use of an agent other than ziprasidone may be preferred (Grunze 2018; Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers are encouraged to enroll women 18 to 45 years of age exposed to ziprasidone during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or https://www.womensmentalhealth.org/pregnancyregistry).</p></div>
<div class="block mopp drugH1Div" id="F53569527"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Vital signs; serum potassium and magnesium; CBC with differential; fasting lipid profile and fasting blood glucose/HbA<sub>1c</sub> (prior to treatment, at 3 months, then annually); weight, BMI, waist circumference; personal/family history of diabetes; blood pressure; mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms. Weight should be assessed prior to treatment, at 4 weeks, 8 weeks, 12 weeks, and then at quarterly intervals. Consider titrating to a different antipsychotic agent for a weight gain ≥5% of the initial weight. Monitor patient periodically for symptom resolution. In children, baseline and periodic (eg, when initially reach steady state, with dose changes or addition of an interacting drug) ECG monitoring in children has been recommended by several pediatric clinicians (Blair 2004; Blair 2005; Elbe 2008; Politte 2014). Discontinue drug in patients found to have persistent QTc intervals &gt;500 msec.</p></div>
<div class="block pha drugH1Div" id="F235856"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ziprasidone is a benzylisothiazolylpiperazine antipsychotic. The exact mechanism of action is unknown. However, <i>in vitro</i> radioligand studies show that ziprasidone has high affinity for D<sub>2</sub>, D<sub>3</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>1D</sub>, and alpha<sub>1</sub>-adrenergic; moderate affinity for histamine H<sub>1</sub> receptors; and no appreciable affinity for alpha<sub>2</sub>-adrenergic receptors, beta-adrenergic, 5-HT<sub>3</sub>, 5-HT<sub>4</sub>, cholinergic, mu, sigma, or benzodiazepine receptors. Ziprasidone functions as an antagonist at the D<sub>2</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>1D</sub> receptors and as an agonist at the 5-HT<sub>1A</sub> receptor. Ziprasidone moderately inhibits the reuptake of serotonin and norepinephrine.</p></div>
<div class="block phk drugH1Div" id="F235872"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Agitation: IM: Initial effects within 15 minutes; adequate sedation within 30 minutes (Martel 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">Bipolar disorder, acute mania: Oral: Initial effects may be observed within days of treatment with continued improvements over 1 to 2 weeks (Goikolea 2013; Tohen 2000; Welten 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">Major depressive disorder, unipolar: Oral: Initial effects may be observed within 1 week with continued improvements over 6 to 12 weeks (Wen 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">Schizophrenia: Oral: Initial effects may be observed within 1 to 2 weeks of treatment with continued improvements through 4 to 6 weeks (Agid 2003; Levine 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed; administration with 500 calorie meals increases serum levels ~80% (Lincoln 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 1.5 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99%, primarily to albumin and alpha-1 acid glycoprotein.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic, primarily chemical and enzymatic reductions via glutathione and aldehyde oxidase, respectively; less than <sup>1</sup>/<sub>3</sub> of total metabolism via CYP3A4 and CYP1A2 (minor).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral (with food): 60%; IM: 100%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Mean terminal half-life:</p>
<p style="text-indent:-2em;margin-left:6em;">Children: Mean: 3.3 to 4.1 hours (Sallee 2006).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 7 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Mean half-life: 2 to 5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Children: Mean: 5 to 5.5 hours (Sallee 2006); Adults: 6 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: ≤60 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~66%; &lt;4% of total dose as unchanged drug); urine (~20%; &lt;1% of total dose as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance:</p>
<p style="text-indent:-2em;margin-left:6em;">Children: Mean: 11.5 to 13.1 mL/minute/kg (Sallee 2006).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: Mean: 7.5 mL/minute/kg.</p></div>
<div class="block phksp drugH1Div" id="F51192018"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Increases the AUC of ziprasidone.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869441"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Zeldox | Ziprasidon actavis | Ziprasidon Krka | Ziprasidon Pfizer | Ziprasidon Ratiopharm | Ziprasidon Stada | Ziprasidon viatris</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo ziprasidone | Zeldox | Ziprasidone gh | Ziprox</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Zipsydon</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Zeldox | Zipwell</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de ziprasidona | Cloridrato de ziprasidona monoidratado | Geodon | Lfm ziprasidona</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Si bei ge | Zeldox</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Geodon</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Zeldox | Ziprasidon Mylan | Zypsilan</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Zeldox | Ziprasidon 1A Pharma | Ziprasidon abz | Ziprasidon actavis | Ziprasidon AL | Ziprasidon Aurobindo | Ziprasidon Beta | Ziprasidon Hexal | Ziprasidon Hormosan | Ziprasidon Mylan | Ziprasidon Neuraxpharm | Ziprasidon Pfizer | Ziprasidon puren | Ziprasidon Ratiopharm | Ziprasidon Stada | Ziprasidone stada | Zipsilan</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Geodon</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Geodon</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ypsila | Zeldox</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Zeldox | Ziprasidona Aurobindo | Ziprasidona aurovitas | Ziprasidona cinfa | Ziprasidona Kern | Ziprasidona Mylan | Ziprasidona normon | Ziprasidona Sandoz | Ziprasidona Stada | Zypsilan</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Zeldox | Ziprasidon Krka | Ziprasidon Pfizer | Ziprasidone Sandoz</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Geodon | Ziprasidone actavis | Ziprasidone Sandoz | Ziprasidone/Generics</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ypsila | Zeldox | Zipwell</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Geodon</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Geodon</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Azona | Zipra | Zipral | Zipsydon</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Zeldox | Ziprasidone Sandoz</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ypsila | Zeldox</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Geodon | Zeldox</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Zeldox | Ziprasidon</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Zeldox | Zusdone</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Geodon | Zeldox</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cara zi | Geodon | Sidone | Xepex | Zap | Zidone | Zipone | Zipra | Ziprasid | Ziprawel | Ziprawin | Ziprawrd | Zipronia | Ziprowin | Zipsilan | Zopeka | Zpras</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Zeldox | Zipragen | Zypsila</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Geodon | Ziprasidone | Ziprasidone HCL | Ziprasidone mesylate</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Zeldox | Ziprasidona Actavis | Ziprasidona Aurobindo | Ziprasidona ciclum | Ziprasidona generis | Ziprasidona Mylan</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Zeldox | Zeldox IM</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Zeldox | Zixadox | Zypsila</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Zeldox | Zipsila</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Geodon | Zeldox | Ziprasidon 2care4 | Ziprasidon actavis | Ziprasidon ebb | Ziprasidon paranova | Ziprasidon Stada | Ziprasidone Sandoz</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Zeldox | Ziprasidon Mylan | Ziprasidon Zentiva | Zipwell</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Zeldox</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Geodon</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Zeldox | Zipradon</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Geodon</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Geodon | Zipsid</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>ACOG Committee on Practice Bulletins-Obstetrics, "ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation," <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14662555">
<a name="14662555"></a>Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected.<i> Arch Gen Psychiatry</i>. 2003;60(12):1228-1235. doi:10.1001/archpsyc.60.12.1228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/14662555/pubmed" id="14662555" target="_blank">14662555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17446198">
<a name="17446198"></a>Akkaya C, Sarandol A, Aydogan K, Kirli S. Urticaria and angio-oedema due to ziprasidone. <i>J Psychopharmacol</i>. 2007;21(5):550-552. doi:10.1177/0269881106075273<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/17446198/pubmed" id="17446198" target="_blank">17446198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20210726">
<a name="20210726"></a>Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. <i>Curr Drug Saf</i>. 2010;5(1):97-104. doi:10.2174/157488610789869265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/20210726/pubmed" id="20210726" target="_blank">20210726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14747245">
<a name="14747245"></a>American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity, “Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes,” <i>Diabetes Care</i>, 2004, 27(2):596-601.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/14747245/pubmed" id="14747245" target="_blank">14747245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15644988">
<a name="15644988"></a>Ananth J, Burgoyne KS, Niz D, Smith M. Tardive dyskinesia in 2 patients treated with ziprasidone. <i>J Psychiatry Neurosci</i>. 2004;29(6):467-469.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/15644988/pubmed" id="15644988" target="_blank">15644988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28861176">
<a name="28861176"></a>Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. <i>World J Diabetes</i>. 2017;8(8):390-396. doi:10.4239/wjd.v8.i8.390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/28861176/pubmed" id="28861176" target="_blank">28861176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36282771">
<a name="36282771"></a>Atkinson S, Bachinsky M, Raiter Y, et al. 26-week open-label extension study evaluating the safety and tolerability of flexible doses of oral ziprasidone in children and adolescents with bipolar I disorder (most recent episode manic). <i>J Child Adolesc Psychopharmacol</i>. 2022;32(8):453-458. doi:10.1089/cap.2022.0030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/36282771/pubmed" id="36282771" target="_blank">36282771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9712220">
<a name="9712220"></a>Bark N. Deaths of psychiatric patients during heat waves.<i> Psychiatr Serv</i>. 1998;49(8):1088-1090. doi:10.1176/ps.49.8.1088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/9712220/pubmed" id="9712220" target="_blank">9712220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17822344">
<a name="17822344"></a>Barzman DH, DelBello MP, Forrester JJ, et al, "A Retrospective Chart Review of Intramuscular Ziprasidone for Agitation in Children and Adolescents on Psychiatric Units: Prospective Studies Are Needed," <i>J Child Adolesc Psychopharmacol</i>, 2007, 17(4):503-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/17822344/pubmed" id="17822344" target="_blank">17822344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23295003">
<a name="23295003"></a>Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. <i>Psychosomatics</i>. 2013;54(1):1-13. doi:10.1016/j.psym.2012.11.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/23295003/pubmed" id="23295003" target="_blank">23295003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33763185">
<a name="33763185"></a>Bell JD, Hall C, Sandall J. Ziprasidone associated neuroleptic malignant syndrome. <i>Kans J Med</i>. 2021;14:82-83. doi:10.17161/kjm.vol1411970<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/33763185/pubmed" id="33763185" target="_blank">33763185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25578944">
<a name="25578944"></a>Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. <i>Drugs R D</i>. 2015;15(1):45-62. doi:10.1007/s40268-014-0078-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/25578944/pubmed" id="25578944" target="_blank">25578944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19958039">
<a name="19958039"></a>Bhuvaneswar CG, Baldessarini RJ, Harsh VL, Alpert JE. Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. <i>CNS Drugs</i>. 2009;23(12):10031021. doi:10.2165/11530020-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/19958039/pubmed" id="19958039" target="_blank">19958039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18076539">
<a name="18076539"></a>Biederman J, Mick E, Spencer T, et al, "A Prospective Open-Label Treatment Trial of Ziprasidone Monotherapy in Children and Adolescents With Bipolar Disorder," <i>Bipolar Disord</i>, 2007, 9(8):888-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/18076539/pubmed" id="18076539" target="_blank">18076539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23983962">
<a name="23983962"></a>Bishop JR, Rubin LH, Reilly JL, Pavuluri MN, Sweeney JA. Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment. <i>Ther Adv Psychopharmacol</i>. 2012;2(3):95-102. doi:10.1177/2045125312442080<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/23983962/pubmed" id="23983962" target="_blank">23983962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15608546">
<a name="15608546"></a>Blair J, Scahill L, State M, et al, "Electrocardiographic Changes in Children and Adolescents Treated With Ziprasidone: A Prospective Study," <i>J Am Acad Child Adolesc Psychiatry</i>, 2005, 44(1):73-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/15608546/pubmed" id="15608546" target="_blank">15608546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15205999">
<a name="15205999"></a>Blair J, Taggart B, and Martin A, "Electrocardiographic Safety Profile and Monitoring Guidelines in Pediatric Psychopharmacology," <i>J Neural Transm</i>, 2004, 111(7):791-815.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/15205999/pubmed" id="15205999" target="_blank">15205999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36515735">
<a name="36515735"></a>Bordet C, Garcia P, Salvo F, Touafchia A, Galinier M, Sommet A, Montastruc F. Antipsychotics and risk of QT prolongation: a pharmacovigilance study. <i>Psychopharmacology (Berl)</i>. 2023;240(1):199-202. doi:10.1007/s00213-022-06293-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/36515735/pubmed" id="36515735" target="_blank">36515735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16352776">
<a name="16352776"></a>Borovicka MC, Bond LC, Gaughan KM. Ziprasidone- and lithium-induced neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2006;40(1):139-142. doi:10.1345/aph.1G470<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/16352776/pubmed" id="16352776" target="_blank">16352776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19113797">
<a name="19113797"></a>Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. <i>Pharmacotherapy</i>. 2009;29(1):64-73. doi:10.1592/phco.29.1.64<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/19113797/pubmed" id="19113797" target="_blank">19113797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17698676">
<a name="17698676"></a>Bouchama A, Dehbi M, Mohamed G, Matthies F, Shoukri M, Menne B. Prognostic factors in heat wave related deaths: a meta-analysis. <i>Arch Intern Med</i>. 2007;167(20):2170-2176. doi:10.1001/archinte.167.20.ira70009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/17698676/pubmed" id="17698676" target="_blank">17698676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20122373">
<a name="20122373"></a>Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. <i>J Clin Psychiatry.</i> 2010;71(2):130-137. doi:10.4088/JCP.09m05482yel<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/20122373/pubmed" id="20122373" target="_blank">20122373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20331935">
<a name="20331935"></a>Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte JA. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. <i>J Clin Psychiatry</i>. 2010;71(3):338-37. doi:10.4088/JCP.08m04595gre<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/20331935/pubmed" id="20331935" target="_blank">20331935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22452529">
<a name="22452529"></a>Camm AJ, Karayal ON, Meltzer H, et al. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data. <i>CNS Drugs.</i> 2012;26(4):351-365. doi:10.2165/11599010-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/22452529/pubmed" id="22452529" target="_blank">22452529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28146614">
<a name="28146614"></a>Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. <i>J Clin Psychiatry</i>. 2017;78(3):e264-e278. doi:10.4088/JCP.16r10832<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/28146614/pubmed" id="28146614" target="_blank">28146614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12927004">
<a name="12927004"></a>Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. <i>J Clin Psychiatry</i>. 2003;64(8):898-906. doi:10.4088/jcp.v64n0807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/12927004/pubmed" id="12927004" target="_blank">12927004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37391174">
<a name="37391174"></a>Carnovale C, Battini V, Santoro C, et al. Umbrella review: association between antipsychotic drugs and metabolic syndrome hallmarks in children and adolescents. <i>J Am Acad Child Adolesc Psychiatry</i>. Published online June 23, 2023. doi:10.1016/j.jaac.2023.04.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/37391174/pubmed" id="37391174" target="_blank">37391174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21172575">
<a name="21172575"></a>Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. <i>Neurol Clin</i>. 2011;29(1):127-148. doi:10.1016/j.ncl.2010.10.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/21172575/pubmed" id="21172575" target="_blank">21172575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15151456">
<a name="15151456"></a>Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. <i>J Clin Psychiatry</i>. 2004;65(Suppl 7):4-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/15151456/pubmed" id="15151456" target="_blank">15151456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23821039">
<a name="23821039"></a>Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. <i>CNS Drugs</i>. 2013;27(7):545-572. doi:10.1007/s40263-013-0079-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/23821039/pubmed" id="23821039" target="_blank">23821039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26455682">
<a name="26455682"></a>Chan VC, La Grenade L, Diak IL, Levin RL. US Food and Drug Administration warning about the risk of drug reaction with eosinophilia and systemic symptoms with ziprasidone. <i>J Clin Psychiatry</i>. 2015;76(9):e1138-e1139. doi:10.4088/JCP.15l09921<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/26455682/pubmed" id="26455682" target="_blank">26455682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22807899">
<a name="22807899"></a>Contreras-Ferrer P, de Paz NM, Cejas-Mendez MR, Rodríguez-Martín M, Souto R, Bustínduy MG. Ziprasidone in the treatment of delusional parasitosis. <i>Case Rep Dermatol</i>. 2012;4(2):150-153.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/22807899/pubmed" id="22807899" target="_blank">22807899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18533766">
<a name="18533766"></a>Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. <i>J Clin Psychiatry</i>. 2008;69(Suppl 4):26-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/18533766/pubmed" id="18533766" target="_blank">18533766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28223031">
<a name="28223031"></a>Crespo-Facorro B, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, et al. Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: analysis of a randomized open-label 1year study. <i>Schizophr Res</i>. 2017;189:134-141. doi:10.1016/j.schres.2017.01.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/28223031/pubmed" id="28223031" target="_blank">28223031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955499">
<a name="29955499"></a>Crouse EL, Alastanos JN, Bozymski KM, Toscano RA. Dysphagia with second-generation antipsychotics: a case report and review of the literature. <i>Ment Health Clin</i>. 2018;7(2):56-64. doi:10.9740/mhc.2017.03.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/29955499/pubmed" id="29955499" target="_blank">29955499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28049388">
<a name="28049388"></a>D'Angelo RG, Rincavage M, Tata AL, et al. Impact of an antipsychotic discontinuation bundle during transitions of care in critically ill patients. <i>J Intensive Care Med.</i> 2019;34(1):40-47. doi:10.1177/0885066616686741<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/28049388/pubmed" id="28049388" target="_blank">28049388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28883731">
<a name="28883731"></a>Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. <i>Neuropsychiatr Dis Treat</i>. 2017;13:2231-2241. doi:10.2147/NDT.S113099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/28883731/pubmed" id="28883731" target="_blank">28883731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23762722">
<a name="23762722"></a>De Berardis D, Serroni N, Marini S, et al. Successful ziprasidone monotherapy in a case of delusional parasitosis: a one-year followup. <i>Case Rep Psychiatry</i>. 2013;2013:913248. doi:10.1155/2013/913248<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/23762722/pubmed" id="23762722" target="_blank">23762722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22009159">
<a name="22009159"></a>De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. <i>Nat Rev Endocrinol</i>. 2011;8(2):114-126. doi:10.1038/nrendo.2011.156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/22009159/pubmed" id="22009159" target="_blank">22009159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DelBello.1">
<a name="DelBello.1"></a>DelBello MP, Findling RL, Wang PP, et al. Efficacy and safety of ziprasidone in pediatric bipolar disorder (2008a). Presented at the 161st Annual Meeting of the American Psychiatric Association (APA); May 3-8, 2008a; Washington DC (poster).</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18928413">
<a name="18928413"></a>DelBello MP, Versavel M, Ice K, et al, "Tolerability of Oral Ziprasidone in Children and Adolescents With Bipolar Mania, Schizophrenia, or Schizoaffective Disorder," <i>J Child Adolesc Psychopharmacol</i>, 2008b, 18(5):491-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/18928413/pubmed" id="18928413" target="_blank">18928413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30113379">
<a name="30113379"></a>Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. <i>Crit Care Med</i>. 2018;46(9):e825-e873. doi:10.1097/CCM.0000000000003299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/30113379/pubmed" id="30113379" target="_blank">30113379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15349021">
<a name="15349021"></a>Dew RE, Hughes D. Acute dystonic reaction with moderate-dose ziprasidone.<i> J Clin Psychopharmacol</i>. 2004;24(5):563-564. doi:10.1097/01.jcp.0000138780.55762.36<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/15349021/pubmed" id="15349021" target="_blank">15349021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24995318">
<a name="24995318"></a>Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. <i>Biomed Res Int</i>. 2014;2014:656370. doi:10.1155/2014/656370<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/24995318/pubmed" id="24995318" target="_blank">24995318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26091194">
<a name="26091194"></a>Dominick K, Wink LK, McDougle CJ, Erickson CA. A retrospective naturalistic study of ziprasidone for irritability in youth with autism spectrum disorder. <i>J Child Adolesc Psychopharmacol</i>. 2015;25(5):397-401.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/26091194/pubmed" id="26091194" target="_blank">26091194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27825323">
<a name="27825323"></a>Druyts E, Zoratti MJ, Toor K, et al. Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: a systematic review. <i>BMC Pediatr</i>. 2016;16(1):181. doi:10.1186/s12887-016-0710-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/27825323/pubmed" id="27825323" target="_blank">27825323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17685744">
<a name="17685744"></a>Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. <i>J Clin Psychiatry.</i> 2007;68(7):1071-1077. doi:10.4088/jcp.v68n0714<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/17685744/pubmed" id="17685744" target="_blank">17685744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19018327">
<a name="19018327"></a>Elbe D and Carandang CG, "Focus on Ziprasidone: A Review of Its Use in Child and Adolescent Psychiatry," <i>J Can Acad Child Adolesc Psychiatry</i>, 2008, 17(4):220-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/19018327/pubmed" id="19018327" target="_blank">19018327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27372312">
<a name="27372312"></a>Fang F, Sun H, Wang Z, Ren M, Calabrese JR, Gao K. Antipsychotic drug-induced somnolence: incidence, mechanisms, and management. <i>CNS Drugs</i>. 2016;30(9):845-867. doi:10.1007/s40263-016-0352-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/27372312/pubmed" id="27372312" target="_blank">27372312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35394365">
<a name="35394365"></a>Findling RL, Atkinson S, Bachinsky M, et al. Efficacy, safety, and tolerability of flexibly dosed ziprasidone in children and adolescents with mania in bipolar I disorder: a randomized placebo-controlled replication study. <i>J Child Adolesc Psychopharmacol</i>. 2022;32(3):143-152. doi:10.1089/cap.2021.0121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/35394365/pubmed" id="35394365" target="_blank">35394365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24111980">
<a name="24111980"></a>Findling RL, Cavuş I, Pappadopulos E, et al. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. <i>J Child Adolesc Psychopharmacol</i>. 2013;23(8):545-557.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/24111980/pubmed" id="24111980" target="_blank">24111980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Findling.1">
<a name="Findling.1"></a>Findling RL, DelBello MP, Wang PP, et al, "Long-Term Safety and Tolerability of Ziprasidone in Pediatric Bipolar Disorder," Presented at the 161st Annual Meeting of the American Psychiatric Association (APA); May 3-8, 2008; Washington DC (poster).<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/Findling.1/pubmed" id="Findling.1" target="_blank">Findling.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18098216">
<a name="18098216"></a>Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. <i>Hum Psychopharmacol</i>. 2008;23(Suppl 1):27-41. doi:10.1002/hup.917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/18098216/pubmed" id="18098216" target="_blank">18098216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25581312">
<a name="25581312"></a>Fraser LA, Liu K, Naylor KL, Hwang YJ, Dixon SN, Shariff SZ, Garg AX. Falls and fractures with atypical antipsychotic medication use: a population-based cohort study. <i>JAMA Intern Med</i>. 2015;175(3):450-452. doi:10.1001/jamainternmed.2014.6930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/25581312/pubmed" id="25581312" target="_blank">25581312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18794644">
<a name="18794644"></a>Freudenmann RW, Lepping P. Second-generation antipsychotics in primary and secondary delusional parasitosis: outcome and efficacy. <i>J Clin Psychopharmacol</i>. 2008;28(5):500-508. doi:10.1097/JCP.0b013e318185e774<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/18794644/pubmed" id="18794644" target="_blank">18794644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26792761">
<a name="26792761"></a>Galling B, Roldán A, Nielsen RE, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. <i>JAMA Psychiatry</i>. 2016;73(3):247-259. doi:10.1001/jamapsychiatry.2015.2923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/26792761/pubmed" id="26792761" target="_blank">26792761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19026256">
<a name="19026256"></a>Gandelman K, Alderman JA, Glue P, et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. <i>J Clin Psychiatry.</i> 2009;70(1):58-62. doi:10.4088/jcp.08m04104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/19026256/pubmed" id="19026256" target="_blank">19026256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Geodon.1">
<a name="Geodon.1"></a>Geodon (ziprasidone) [prescribing information]. New York, NY: Pfizer Inc; February 2022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/Geodon.1/pubmed" id="Geodon.1" target="_blank">Geodon.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18606348">
<a name="18606348"></a>Gibbons GM, Wein DA, Paula R. Profound hypothermia secondary to normal ziprasidone use.<i> Am J Emerg Med</i>. 2008;26(6):737.e1-2. doi:10.1016/j.ajem.2007.11.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/18606348/pubmed" id="18606348" target="_blank">18606348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17548409">
<a name="17548409"></a>Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. <i>Ann Intern Med</i>. 2007;146(11):775-786. doi:10.7326/0003-4819-146-11-200706050-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/17548409/pubmed" id="17548409" target="_blank">17548409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30346242">
<a name="30346242"></a>Girard TD, Exline MC, Carson SS, et al; MIND-USA Investigators. Haloperidol and ziprasidone for treatment of delirium in critical illness. <i>N Engl J Med</i>. 2018;379(26):2506-2516. doi:10.1056/NEJMoa1808217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/30346242/pubmed" id="30346242" target="_blank">30346242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20095068">
<a name="20095068"></a>Girard TD, Pandharipande PP, Carson SS, et al; MIND Trial Investigators. Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. <i>Crit Care Med</i>. 2010;38(2):428-437. doi:10.1097/ccm.0b013e3181c58715<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/20095068/pubmed" id="20095068" target="_blank">20095068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22841129">
<a name="22841129"></a>Goikolea JM, Colom F, Capapey J, et al. Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. <i>Eur Neuropsychopharmacol</i>. 2013;23(4):305-316. doi:10.1016/j.euroneuro.2012.05.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/22841129/pubmed" id="22841129" target="_blank">22841129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17627670">
<a name="17627670"></a>Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. <i>CNS Drug Rev</i>. 2007;13(2):137-177. doi:10.1111/j.1527-3458.2007.00008.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/17627670/pubmed" id="17627670" target="_blank">17627670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29098925">
<a name="29098925"></a>Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder. <i>World J Biol Psychiatry</i>. 2018;19(1):2‐58. doi:10.1080/15622975.2017.1384850<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/29098925/pubmed" id="29098925" target="_blank">29098925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21790209">
<a name="21790209"></a>Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. <i>CNS Drugs</i>. 2011;25(8):659-671. doi:10.2165/11591710-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/21790209/pubmed" id="21790209" target="_blank">21790209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15456328">
<a name="15456328"></a>Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. <i>Drugs</i>. 2004;64(20):2291-2314. doi:10.2165/00003495-200464200-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/15456328/pubmed" id="15456328" target="_blank">15456328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18941580">
<a name="18941580"></a>Hansen A, Bi P, Nitschke M, Ryan P, Pisaniello D, Tucker G. The effect of heat waves on mental health in a temperate Australian city. <i>Environ Health Perspect</i>. 2008;116(10):1369-1375. doi:10.1289/ehp.11339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/18941580/pubmed" id="18941580" target="_blank">18941580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22834451">
<a name="22834451"></a>Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378. doi:10.3109/15622975.2012.696143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/22834451/pubmed" id="22834451" target="_blank">22834451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HazardousDrugs.1">
<a name="HazardousDrugs.1"></a>Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HealthCanada.1">
<a name="HealthCanada.1"></a>Healthy Canadians Recalls &amp; Alerts: Summary Safety Review - Atypical antipsychotics - assessing the potential risk of sleep apnoea. Health Canada website. Available at: <a href="http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/antipsycho2-eng.php" target="_blank">http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/antipsycho2-eng.php</a>. Published August 16, 2016. Accessed August 23, 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/HealthCanada.1/pubmed" id="HealthCanada.1" target="_blank">HealthCanada.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16684946">
<a name="16684946"></a>Heinrich TW, Biblo LA, Schneider J. Torsades de pointes associated with ziprasidone. <i>Psychosomatics</i>. 2006;47(3):264-268. doi:10.1176/appi.psy.47.3.264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/16684946/pubmed" id="16684946" target="_blank">16684946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29095482">
<a name="29095482"></a>Herzig SJ, LaSalvia MT, Naidus E, et al. Antipsychotics and the risk of aspiration pneumonia in individuals hospitalized for nonpsychiatric conditions: a cohort study. <i>J Am Geriatr Soc</i>. 2017;65(12):2580-2586. doi:10.1111/jgs.15066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/29095482/pubmed" id="29095482" target="_blank">29095482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62. doi:10.1055/s-0043-116492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16633146">
<a name="16633146"></a>Holzer L, Eap CB. Risperidone-induced symptomatic hyperprolactinaemia in adolescents. <i>J Clin Psychopharmacol</i>. 2006;26(2):167-171. doi:10.1097/01.jcp.0000203194.58087.9a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/16633146/pubmed" id="16633146" target="_blank">16633146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23680062">
<a name="23680062"></a>Honigberg MC, Bui MP, Coconcea C. A case of ziprasidone associated with acutely worsened diabetes mellitus. <i>Psychosomatics</i>. 2013;54(3):304-305. doi:10.1016/j.psym.2012.08.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/23680062/pubmed" id="23680062" target="_blank">23680062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10671383">
<a name="10671383"></a>Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. <i>Am J Psychiatry</i>. 2000;157(2):172-178. doi:10.1176/appi.ajp.157.2.172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/10671383/pubmed" id="10671383" target="_blank">10671383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29924506">
<a name="29924506"></a>Hsu JH, Mulsant BH, Lenze EJ, et al. Clinical predictors of extrapyramidal symptoms associated with aripiprazole augmentation for the treatment of late-life depression in a randomized controlled trial. <i>J Clin Psychiatry</i>. 2018;79(4):17m11764. doi: 10.4088/JCP.17m11764<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/29924506/pubmed" id="29924506" target="_blank">29924506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25140533">
<a name="25140533"></a>Jackson JW, Schneeweiss S, VanderWeele TJ, Blacker D. Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis. <i>PLoS One</i>. 2014;9(8):e105376. doi:10.1371/journal.pone.0105376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/25140533/pubmed" id="25140533" target="_blank">25140533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24416588">
<a name="24416588"></a>Jones ME, Campbell G, Patel D, et al. Risk of mortality (including sudden cardiac death) and major cardiovascular events in users of olanzapine and other antipsychotics: a study with the General Practice Research Database. <i>Cardiovasc Psychiatry Neurol</i>. 2013;2013:647476. doi:10.1155/2013/647476<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/24416588/pubmed" id="24416588" target="_blank">24416588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3819263">
<a name="3819263"></a>Jurivich DA, Hanlon J, Andolsek K. Neuroleptic-induced neutropenia in the elderly. <i>J Am Geriatr Soc</i>. 1987;35(3):248-250. doi:10.1111/j.1532-5415.1987.tb02317.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/3819263/pubmed" id="3819263" target="_blank">3819263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24474994">
<a name="24474994"></a>Karamustafalioglu N, Kalelioglu T, Tanriover O, Gungor FC, Genc A, Ilnem C. A case report of priapism caused by ziprasidon. <i>Psychiatry Investig</i>. 2013;10(4):425-427. doi:10.4306/pi.2013.10.4.425<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/24474994/pubmed" id="24474994" target="_blank">24474994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14702272">
<a name="14702272"></a>Keck ME, Müller MB, Binder EB, Sonntag A, Holsboer F. Ziprasidone-related tardive dyskinesia.<i> Am J Psychiatry</i>. 2004;161(1):175-176. doi:10.1176/appi.ajp.161.1.175-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/14702272/pubmed" id="14702272" target="_blank">14702272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32867516">
<a name="32867516"></a>Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. <i>Am J Psychiatry.</i> 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/32867516/pubmed" id="32867516" target="_blank">32867516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17201611">
<a name="17201611"></a>Khan SS and Mican LM, "A Naturalistic Evaluation of Intramuscular Ziprasidone Versus Intramuscular Olanzapine for the Management of Acute Agitation and Aggression in Children and Adolescents," <i>J Child Adolesc Psychopharmacol</i>, 2006, 16(6):671-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/17201611/pubmed" id="17201611" target="_blank">17201611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24649390">
<a name="24649390"></a>Khasawneh FT, Shankar GS. Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia. <i>Cardiol Res Pract</i>. 2014;2014:273060. doi:10.1155/2014/273060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/24649390/pubmed" id="24649390" target="_blank">24649390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24117439">
<a name="24117439"></a>Kim MS, Kim SW, Han TY, Son SJ, Lee JH, Kim EJ. Ziprasidone-induced hypersensitivity syndrome confirmed by reintroduction. <i>Int J Dermatol</i>. 2014;53(4):e267-e268. doi:10.1111/ijd.12246<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/24117439/pubmed" id="24117439" target="_blank">24117439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12766935">
<a name="12766935"></a>Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome--a case review. <i>Hum Psychopharmacol</i>. 2003;18(4):301-309. doi:10.1002/hup.483<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/12766935/pubmed" id="12766935" target="_blank">12766935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15869022">
<a name="15869022"></a>Koro CE, Meyer JM. Atypical antipsychotic therapy and hyperlipidemia: a review. <i>Essent Psychopharmacol</i>. 2005;6(3):148-157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/15869022/pubmed" id="15869022" target="_blank">15869022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16174785">
<a name="16174785"></a>Kwok JS, Chan TY. Recurrent heat-related illnesses during antipsychotic treatment. <i>Ann Pharmacother</i>. 2005;39(11):1940-1942. doi:10.1345/aph.1G130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/16174785/pubmed" id="16174785" target="_blank">16174785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17650054">
<a name="17650054"></a>Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. <i>J Clin Psychiatry</i>. 2007;68(suppl 6):10-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/17650054/pubmed" id="17650054" target="_blank">17650054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24016844">
<a name="24016844"></a>Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbæk G. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. <i>Am J Geriatr Psychiatry</i>. 2014;22(4):321-331. doi:10.1016/j.jagp.2013.06.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/24016844/pubmed" id="24016844" target="_blank">24016844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al; Danish Psychiatric Society; Danish Society of Obstetrics and Gynecology; Danish Paediatric Society; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1‐28. doi:10.1111/acps.12479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15000267">
<a name="15000267"></a>Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2 Suppl):1-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/15000267/pubmed" id="15000267" target="_blank">15000267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21881458">
<a name="21881458"></a>Létourneau G, Abdel-Baki A, Dubreucq S, Mahone M, Granger B. Hyperosmolar hyperglycemic state associated with ziprasidone treatment: a case report. <i>J Clin Psychopharmacol</i>. 2011;31(5):671-673. doi:10.1097/JCP.0b013e31822c96b7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/21881458/pubmed" id="21881458" target="_blank">21881458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18849294">
<a name="18849294"></a>Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. <i>Schizophr Bull.</i> 2010;36(3):624-632. doi:10.1093/schbul/sbn120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/18849294/pubmed" id="18849294" target="_blank">18849294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20511734">
<a name="20511734"></a>Lincoln J, Steward ME, Preskorn SH. How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone. <i>J Psychiatr Pract</i>. 2010;16(2):103-114. doi:10.1097/01.pra.0000369971.64908.dc<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/20511734/pubmed" id="20511734" target="_blank">20511734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20602736">
<a name="20602736"></a>Lin PY, Hong CJ, Tsai SJ. Serotonin syndrome caused by ziprasidone alone. <i>Psychiatry Clin Neurosci</i>. 2010;64(3):338-339. doi:10.1111/j.1440-1819.2010.02086.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/20602736/pubmed" id="20602736" target="_blank">20602736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28791693">
<a name="28791693"></a>Loy JH, Merry SN, Hetrick SE, Stasiak K. Atypical antipsychotics for disruptive behaviour disorders in children and youths. <i>Cochrane Database Syst Rev</i>. 2017;8:CD008559.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/28791693/pubmed" id="28791693" target="_blank">28791693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20213839">
<a name="20213839"></a>Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). <i>J Pharm Sci</i>. 2010;99(8):3291-3301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/20213839/pubmed" id="20213839" target="_blank">20213839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15465997">
<a name="15465997"></a>Lusskin SI, Cancro R, Chuang L, Jacobson J. Prolactin elevation with ziprasidone. <i>Am J Psychiatry</i>. 2004;161(10):1925. doi:10.1176/ajp.161.10.1925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/15465997/pubmed" id="15465997" target="_blank">15465997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15138897">
<a name="15138897"></a>Maddalena AS, Fox M, Hofmann M, Hock C. Esophageal dysfunction on psychotropic medication. A case report and literature review. <i>Pharmacopsychiatry</i>. 2004;37(3):134-138.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/15138897/pubmed" id="15138897" target="_blank">15138897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18315450">
<a name="18315450"></a>Malone RP, Delaney MA, Hyman SB, et al, "Ziprasidone in Adolescents With Autism: An Open-Label Pilot Study," <i>J Child Adolesc Psychopharmacol</i>, 2007, 17(6):779-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/18315450/pubmed" id="18315450" target="_blank">18315450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26818629">
<a name="26818629"></a>Marshall J, Herzig SJ, Howell MD, et al. Antipsychotic utilization in the intensive care unit and in transitions of care. <i>J Crit Care.</i> 2016;33:119-124. doi:10.1016/j.jcrc.2015.12.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/26818629/pubmed" id="26818629" target="_blank">26818629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16282517">
<a name="16282517"></a>Martel M, Sterzinger A, Miner J, Clinton J, Biros M. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. <i>Acad Emerg Med</i>. 2005;12(12):1167-1172. doi:10.1197/j.aem.2005.07.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/16282517/pubmed" id="16282517" target="_blank">16282517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12190212">
<a name="12190212"></a>Martinez M, Devenport L, Saussy J, Martinez J. Drug-associated heat stroke. <i>South Med J</i>. 2002;95(8):799-802.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/12190212/pubmed" id="12190212" target="_blank">12190212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25786075">
<a name="25786075"></a>Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. <i>JAMA Psychiatry</i>. 2015;72(5):438-445. doi:10.1001/jamapsychiatry.2014.3018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/25786075/pubmed" id="25786075" target="_blank">25786075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12164181">
<a name="12164181"></a>McDougle CJ, Kem DL, and Posey DJ, "Case Series: Use of Ziprasidone for Maladaptive Symptoms in Youths With Autism," <i>J Am Acad Child Adolesc Psychiatry</i>, 2002, 41(8):921-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/12164181/pubmed" id="12164181" target="_blank">12164181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mechcatie.1">
<a name="Mechcatie.1"></a>Mechcatie, E, "MD Consult: News: Mixed Votes on Ziprasidone's Safety and Efficacy for Pediatric Indications," June 16, 2009. Date accessed: January 20, 2010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/Mechcatie.1/pubmed" id="Mechcatie.1" target="_blank">Mechcatie.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32670542">
<a name="32670542"></a>Moncrieff J, Gupta S, Horowitz MA. Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder. <i>Ther Adv Psychopharmacol</i>. Published online July 6, 2020. doi:10.1177/2045125320937910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/32670542/pubmed" id="32670542" target="_blank">32670542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16377373">
<a name="16377373"></a>Montgomery J. Ziprasidone-related agranulocytosis following olanzapine-induced neutropenia. <i>Gen Hosp Psychiatry</i>. 2006;28(1):83-85. doi:10.1016/j.genhosppsych.2005.08.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/16377373/pubmed" id="16377373" target="_blank">16377373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moore.2020">
<a name="Moore.2020"></a>Moore GP, Moore MJ. Assessment and emergency management of the acutely agitated or violent adult. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 27, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/Moore.2020/pubmed" id="Moore.2020" target="_blank">Moore.2020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8102845">
<a name="8102845"></a>Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. <i>Arch Gen Psychiatry</i>. 1993;50(9):723-733. doi:10.1001/archpsyc.1993.01820210057007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/8102845/pubmed" id="8102845" target="_blank">8102845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20187598">
<a name="20187598"></a>Muench J, Hamer AM. Adverse effects of antipsychotic medications.<i> Am Fam Physician</i>. 2010;81(5):617-622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/20187598/pubmed" id="20187598" target="_blank">20187598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12454565">
<a name="12454565"></a>Murty RG, Mistry SG, Chacko RC. Neuroleptic malignant syndrome with ziprasidone.<i> J Clin Psychopharmacol</i>. 2002;22(6):624-626. doi:10.1097/00004714-200212000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/12454565/pubmed" id="12454565" target="_blank">12454565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15765830">
<a name="15765830"></a>Nair P, Lippmann S. Blood dyscrasia with quetiapine and ziprasidone. <i>Psychosomatics</i>. 2005;46(1):89-90. doi:10.1176/appi.psy.46.1.89<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/15765830/pubmed" id="15765830" target="_blank">15765830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15823759">
<a name="15823759"></a>Newcomer JW. Metabolic risk during antipsychotic treatment. <i>Clin Ther</i>. 2004;26(12):1936-1946. doi:10.1016/j.clinthera.2004.12.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/15823759/pubmed" id="15823759" target="_blank">15823759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28205446">
<a name="28205446"></a>Nguyen T, Stanton J, Foster R. Intramuscular ziprasidone dosing for acute agitation in the pediatric emergency department: an observational study. <i>J Pharm Pract</i>. 2018;31(1):18-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/28205446/pubmed" id="28205446" target="_blank">28205446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20520598">
<a name="20520598"></a>Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. <i>Neuropsychopharmacology</i>. 2010;35(9):1997-2004. doi:10.1038/npp.2010.78<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/20520598/pubmed" id="20520598" target="_blank">20520598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22854034">
<a name="22854034"></a>Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. <i>Can J Psychiatry</i>. 2012;57(8):512-518. doi: 10.1177/070674371205700810<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/22854034/pubmed" id="22854034" target="_blank">22854034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14565800">
<a name="14565800"></a>O'Neill JL, Remington TL. Drug-induced esophageal injuries and dysphagia. <i>Ann Pharmacother</i>. 2003;37(11):1675-1684. doi:10.1345/aph.1D056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/14565800/pubmed" id="14565800" target="_blank">14565800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17366349">
<a name="17366349"></a>Ozen ME, Yumru M, Savas HA, Cansel N, Herken H. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.<i> World J Biol Psychiatry</i>. 2007;8(1):42-44. doi:10.1080/15622970600774202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/17366349/pubmed" id="17366349" target="_blank">17366349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28219485">
<a name="28219485"></a>Pagsberg AK, Tarp S, Glintborg D, et al. Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. <i>J Am Acad Child Adolesc Psychiatry</i>. 2017;56(3):191-202.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/28219485/pubmed" id="28219485" target="_blank">28219485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26085041">
<a name="26085041"></a>Papakostas GI, Fava M, Baer L, et al. Ziprasidone augmentation of escitalopram for major depressive disorder: efficacy results from a randomized, double-blind, placebo-controlled study. <i>Am J Psychiatry</i>. 2015;172(12):1251-1258. doi:10.1176/appi.ajp.2015.14101251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/26085041/pubmed" id="26085041" target="_blank">26085041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31325958">
<a name="31325958"></a>Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis.<i> BMC Neurol</i>. 2019;19(1):174. doi:10.1186/s12883-019-1385-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/31325958/pubmed" id="31325958" target="_blank">31325958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9735957">
<a name="9735957"></a>Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. <i>Psychiatr Serv</i>. 1998;49(9):1163-1172. doi:10.1176/ps.49.9.1163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/9735957/pubmed" id="9735957" target="_blank">9735957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24677189">
<a name="24677189"></a>Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. <i>CNS Drugs</i>. 2014;28(5):421-453. doi:10.1007/s40263-014-0157-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/24677189/pubmed" id="24677189" target="_blank">24677189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23552907">
<a name="23552907"></a>Politte LC, McDougle CJ. Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders. <i>Psychopharmacology (Berl)</i>. 2014;231(6):1023-1036.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/23552907/pubmed" id="23552907" target="_blank">23552907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Post.1">
<a name="Post.1"></a>Post RM. Bipolar disorder in adults: Choosing maintenance treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 30, 2021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/Post.1/pubmed" id="Post.1" target="_blank">Post.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23698184">
<a name="23698184"></a>Praharaj SK, Jana AK, Sarkhel S, Sinha VK. Acute dystonia, akathisia, and parkinsonism induced by ziprasidone. <i>Am J Ther.</i> 2014;21(2):e38-40. doi:10.1097/MJT.0b013e318230ae52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/23698184/pubmed" id="23698184" target="_blank">23698184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20944784">
<a name="20944784"></a>Raza S, Haq F. Ziprasidone-induced galactorrhea in an adolescent female: a case report. <i>Prim Care Companion J Clin Psychiatry</i>. 2010;12(3):PCC.09l00855. doi:10.4088/PCC.09l00855gry<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/20944784/pubmed" id="20944784" target="_blank">20944784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/Manu.1/pubmed" id="Manu.1" target="_blank">Manu.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15949658">
<a name="15949658"></a>Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? <i>Schizophr Res</i>. 2005;76(2-3):267-272. doi:10.1016/j.schres.2005.01.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/15949658/pubmed" id="15949658" target="_blank">15949658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27133416">
<a name="27133416"></a>Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. <i>Am J Psychiatry</i>. 2016;173(5):543-546. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2015.173501. Accessed May 26, 2016. doi:10.1176/appi.ajp.2015.173501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/27133416/pubmed" id="27133416" target="_blank">27133416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26218604">
<a name="26218604"></a>Rojo LE, Gaspar PA, Silva H, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. <i>Pharmacol Res</i>. 2015;101:74-85. doi:10.1016/j.phrs.2015.07.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/26218604/pubmed" id="26218604" target="_blank">26218604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20871665">
<a name="20871665"></a>Rosenbloom AL. Hyperprolactinemia with antipsychotic drugs in children and adolescents. <i>Int J Pediatr Endocrinol</i>. 2010;2010:159402. doi:10.1155/2010/159402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/20871665/pubmed" id="20871665" target="_blank">20871665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rothschild.2020">
<a name="Rothschild.2020"></a>Rothschild AJ. Unipolar major depression with psychotic features: acute treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 4, 2020</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23218157">
<a name="23218157"></a>Sachs GS, Vanderburg DG, Karayal ON, Kolluri S, Bachinsky M, Cavus I. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.<i> J Clin Psychiatry.</i> 2012;73(11):1412-1419. doi:10.4088/JCP.11m07388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/23218157/pubmed" id="23218157" target="_blank">23218157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10714048">
<a name="10714048"></a>Sallee FR, Kurlan R, Goetz CG, et al, “Ziprasidone Treatment of Children and Adolescents With Tourette's Syndrome: A Pilot Study,” <i>J Am Acad Child Adolesc Psychiatry</i>, 2000, 39(3):292-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/10714048/pubmed" id="10714048" target="_blank">10714048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16721322">
<a name="16721322"></a>Sallee FR, Miceli JJ, Tensfeldt T, Robarge L, Wilner K, Patel NC. Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. <i>J Am Acad Child Adolesc Psychiatry</i>. 2006;45(6):720-728.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/16721322/pubmed" id="16721322" target="_blank">16721322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17404121">
<a name="17404121"></a>Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. <i>Arch Gen Psychiatry.</i> 2007;64(4):442-455. doi:10.1001/archpsyc.64.4.442<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/17404121/pubmed" id="17404121" target="_blank">17404121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19203410">
<a name="19203410"></a>Schlotterbeck P, Saur R, Hiemke C, et al. Low concentration of ziprasidone in human milk: a case report. <i>Int J Neuropsychopharmacol</i>. 2009;12(3):437‐438. doi:10.1017/S1461145709009936<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/19203410/pubmed" id="19203410" target="_blank">19203410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19485732">
<a name="19485732"></a>Scott LK, Green R, McCarthy PJ, et al, "Agitation and/or Aggression After Traumatic Brain Injury in the Pediatric Population Treated With Ziprasidone. Clinical Article," <i>J Neurosurg Pediatr</i>, 2009, 3(6):484-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/19485732/pubmed" id="19485732" target="_blank">19485732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19213967">
<a name="19213967"></a>Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. <i>Psychosomatics</i>. 2009;50(1):8-15. doi:10.1176/appi.psy.50.1.8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/19213967/pubmed" id="19213967" target="_blank">19213967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23251855">
<a name="23251855"></a>Sethi R, Kavuru B. Hypothermia secondary to ziprasidone use in a man with schizophrenia. <i>Prim Care Companion CNS Disord</i>. 2012;14(4):PCC.11l01338. doi:10.4088/PCC.11l01338.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/23251855/pubmed" id="23251855" target="_blank">23251855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24847993">
<a name="24847993"></a>Shah AA, Aftab A, Coverdale J. QTc prolongation with antipsychotics: is routine ECG monitoring recommended? <i>J Psychiatr Pract.</i> 2014;20(3):196-206. doi:10.1097/01.pra.0000450319.21859.6d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/24847993/pubmed" id="24847993" target="_blank">24847993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21645873">
<a name="21645873"></a>Shirani A, Paradiso S, Dyken ME. The impact of atypical antipsychotic use on obstructive sleep apnea: a pilot study and literature review. <i>Sleep Med</i>. 2011;12(6):591-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/21645873/pubmed" id="21645873" target="_blank">21645873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17390261">
<a name="17390261"></a>Soares-Weiser K, Fernandez HH. Tardive dyskinesia. <i>Semin Neurol</i>. 2007;27(2):159-169.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/17390261/pubmed" id="17390261" target="_blank">17390261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28721057">
<a name="28721057"></a>Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. <i>Ther Clin Risk Manag</i>. 2017;13:757-777.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/28721057/pubmed" id="28721057" target="_blank">28721057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29439776">
<a name="29439776"></a>Solmi M, Pigato G, Kane JM, et al. Clinical risk factors for the development of tardive dyskinesia. <i>J Neurol Sci</i>. 2018;389:21-27. doi:10.1016/j.jns.2018.02.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/29439776/pubmed" id="29439776" target="_blank">29439776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15662151">
<a name="15662151"></a>Staller JA, "Intramuscular Ziprasidone in Youth: A Retrospective Chart Review," <i>J Child Adolesc Psychopharmacol</i>, 2004, 14(4):590-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/15662151/pubmed" id="15662151" target="_blank">15662151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stovall.2020">
<a name="Stovall.2020"></a>Stovall J. Bipolar mania and hypomania in adults: choosing pharmacotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/Stovall.2020/pubmed" id="Stovall.2020" target="_blank">Stovall.2020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30192094">
<a name="30192094"></a>Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. <i>World Psychiatry</i>. 2018;17(3):341-356. doi:10.1002/wps.20567<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/30192094/pubmed" id="30192094" target="_blank">30192094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stroup.1">
<a name="Stroup.1"></a>Stroup TS, Marder S. Schizophrenia in adults: maintenance therapy and side effect management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 28, 2022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/Stroup.1/pubmed" id="Stroup.1" target="_blank">Stroup.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Suh.2020">
<a name="Suh.2020"></a>Suh KN. Treatment of delusional infestation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 27, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/Suh.2020/pubmed" id="Suh.2020" target="_blank">Suh.2020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28044008">
<a name="28044008"></a>Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G. Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. <i>Schizophr Bull</i>. 2017;43(4):862-871. doi:10.1093/schbul/sbw171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/28044008/pubmed" id="28044008" target="_blank">28044008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tietze.1">
<a name="Tietze.1"></a>Tietze K. Sedative-analgesic medications in critically ill adults: Properties, dose regimens, and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 3, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/Tietze.1/pubmed" id="Tietze.1" target="_blank">Tietze.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24803473">
<a name="24803473"></a>Tisdale JE, Jaynes HA, Kingery JR, Overholser BR, Mourad NA, Trujillo TN, Kovacs RJ. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(3):381-390. doi:10.1161/CIRCOUTCOMES.113.000651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/24803473/pubmed" id="24803473" target="_blank">24803473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11249804">
<a name="11249804"></a>Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. <i>Bipolar Disord</i>. 2000;2(3 Pt 2):261-268. doi:10.1034/j.1399-5618.2000.20307.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/11249804/pubmed" id="11249804" target="_blank">11249804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed January 5, 2024.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/HHS.1/pubmed" id="HHS.1" target="_blank">HHS.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10473482">
<a name="10473482"></a>van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. <i>BMJ</i>. 1999;319(7210):623-626. doi:10.1136/bmj.319.7210.623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/10473482/pubmed" id="10473482" target="_blank">10473482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17401555">
<a name="17401555"></a>van Marum RJ, Wegewijs MA, Loonen AJ, Beers E. Hypothermia following antipsychotic drug use. <i>Eur J Clin Pharmacol</i>. 2007;63(6):627-631. doi:10.1007/s00228-007-0294-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/17401555/pubmed" id="17401555" target="_blank">17401555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18348593">
<a name="18348593"></a>van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. <i>J Clin Psychiatry</i>. 2008;69(3):472-479. doi:10.4088/jcp.v69n0320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/18348593/pubmed" id="18348593" target="_blank">18348593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23858394">
<a name="23858394"></a>Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. T<i>remor Other Hyperkinet Mov (N Y)</i>. 2013;3:tre-03-161-4138-1. doi:10.7916/D88P5Z71<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/23858394/pubmed" id="23858394" target="_blank">23858394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27032095">
<a name="27032095"></a>Wang B, Franklin JM, Eddings W, Landon J, Kesselheim AS. Did FDA decision making affect anti-psychotic drug prescribing in children?: a time-trend analysis. <i>PLoS One</i>. 2016;11(3):e0152195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/27032095/pubmed" id="27032095" target="_blank">27032095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27780320">
<a name="27780320"></a>Welten CC, Koeter MW, Wohlfarth TD, et al. Early nonresponse in the antipsychotic treatment of acute mania: a criterion for reconsidering treatment? Results from an individual patient data meta-analysis. <i>J Clin</i>
<i>Psychiatry</i>. 2016;77(9):e1117-e1123. doi:10.4088/JCP.15r10051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/27780320/pubmed" id="27780320" target="_blank">27780320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24919175">
<a name="24919175"></a>Wen XJ, Wang LM, Liu ZL, Huang A, Liu YY, Hu JY. Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder. <i>Braz J Med Biol Res</i>. 2014;47(7):605-616. doi:10.1590/1414-431x20143672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/24919175/pubmed" id="24919175" target="_blank">24919175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22461918">
<a name="22461918"></a>Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry project Beta psychopharmacology workgroup. <i>West J Emerg Med</i>. 2012;13(1):26-34. doi:10.5811/westjem.2011.9.6866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/22461918/pubmed" id="22461918" target="_blank">22461918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25497507">
<a name="25497507"></a>Wu CY, Mitchell SR, Seyfried LS. Quetiapine-induced hyperglycemic crisis and severe hyperlipidemia: a case report and review of the literature. <i>Psychosomatics</i>. 2014;55(6):686-691. doi:10.1016/j.psym.2014.07.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/25497507/pubmed" id="25497507" target="_blank">25497507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536616">
<a name="29536616"></a>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disord</i>. 2018;20(2):97-170. doi:10.1111/bdi.12609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/29536616/pubmed" id="29536616" target="_blank">29536616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32237292">
<a name="32237292"></a>Zhang Y, Wang Q, Reynolds GP, et al. Metabolic effects of 7 antipsychotics on patients with schizophrenia: a short-rerm, randomized, open-label, multicenter, pharmacologic trial. <i>J Clin Psychiatry</i>. 2020;81(3):19m12785. doi:10.4088/JCP.19m12785<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/32237292/pubmed" id="32237292" target="_blank">32237292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28936184">
<a name="28936184"></a>Zonnenberg C, Bueno-de-Mesquita JM, Ramlal D, Blom JD. Hypothermia due to antipsychotic medication: a systematic review. <i>Front Psychiatry</i>. 2017;8:165. doi:10.3389/fpsyt.2017.00165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ziprasidone-pediatric-drug-information/abstract-text/28936184/pubmed" id="28936184" target="_blank">28936184</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 15622 Version 496.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
